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ABSTRACT
Chronic Stress, Depressive Symptoms and Peripheral Vascular Dysfunction: Fundamentals, Mechanisms,
Sex Disparities, and Determinants of Integrated Outcomes

Shyla Christine Stanley
Chronic, irresolvable psychological stress, a major contributor of depressive disorders, has been identified
as a key factor involved in the association between the prevalence/severity of depressive symptoms and the
concurrent development of cardiovascular disease (CVD). Furthermore, there are marked differences in the
incidence and pathology of these diseases between males and females, although the mechanisms involved are
unclear. The purpose of this dissertation is to investigate the effects of chronic stress/depression on behavioral and
vascular function in rodents in order to elucidate the underlying mechanisms linking depressive symptom severity
with cardiovascular development/outcome. The unpredictable chronic mild stress (UCMS) model is well
recognized in behavioral studies as a translationally appropriate animal model for generating depressive
symptoms in rodents that accurately reflect human clinical characteristics, including learned helplessness and
anhedonia (Willner et al., 1997; Yalcin et al., 2008). This model is based on the fundamental concept that chronic
exposure to uncontrollable exogenous stressors will ultimately lead to depressive disorders (Mineur et al., 2003).
This model will be used to compare functional outcomes (relative to behavior and CVD risk) between males and
females, as well as the effects of this chronic stress regimen in animals with pre-existing cardiovascular risk.
The differential effects of UCMS on depressive symptom severity and vascular function on male and
female rodents were initially performed using the BALB/cJ mouse (Chapter 1 of this dissertation). The following
experiments (Chapters 2 and 3) utilized male and female lean and obese Zucker rats (LZR and OZR) as a
comorbid animal model of metabolic syndrome (MetS). Furthermore, ovariectomized (OVX) female LZR and
OZR were utilized in order to further investigate sex specific mechanisms involved in cardiovascular and
behavioral outcomes to UCMS. The OZR develop similar symptoms of MetS observed in humans due to a
genetic mutation in the leptin receptor gene that causes loss of satiety signaling, thus leading to chronic
hyperphagia and the subsequent onset of obesity, hyperglycemia, insulin resistance, dyslipidemia, and moderate
hypertension. MetS, which affects 34% of adults (≥ 20 years of age) in the United States, is generally defined by
the presence of a constellation of comorbid factors (abdominal obesity, insulin resistance, atherogenic

dyslipidemia, pro-inflammatory/pro-thrombotic state) that are significantly associated with increased CVD risk
(American Heart Association, 2014). The OZR also progressively develop non-atherosclerotic peripheral vascular
disease in addition to severe vascular impairments, and therefore represents a relevant model of underlying CVD
risk.
This dissertation addresses the differential sex-specific effects of UCMS-induced chronic stress on
depressive-like behavioral severity and the severity of impaired vascular responsivity to endothelial dependent
vasodilator stimuli, as well as the specific mechanisms underlying stress- induced vascular dysfunction, between
male and female rodents. These functional outcomes were interrogated in male and female OZR (versus lean
rodents, LZR) to determine the consequences of UCMS-induced chronic stress/depressive symptoms on rodents
with pre-existing MetS. Finally, the effects of UCMS were investigated in OVX LZR and OZR to determine the
implications of loss of female sex hormones on behavior and cardiovascular function in both healthy and obese
female rodents.
Specific Aims:
Aim 1: To determine the impact of UCMS on vascular reactivity in mice of both sexes. It is hypothesized that
UCMS will result in a more severe development of depressive symptoms in female mice (vs. males), but vascular
function will be superior to that of males.
Aim 2: To determine if the protective effect against UCMS-induced vasculopathy in females is altered in rats
with pre-existing cardiovascular disease risk factors and/or following OVX. It is hypothesized that vascular
function in female animals will no longer be protected from UCMS-induced impairments in animals with
comorbid CVD risk factors or in animals having undergone OVX.
Aim 3: To determine the impact of pharmacological interventions on chronic stress/depressive symptoms and
vascular function in male animals with pre-existing cardiovascular disease risk factors. It is predicted that
improving CVD risk and vascular function with drugs will improve behavioral symptoms/corticosterone levels.
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INTRODUCTION
Cardiovascular Disease (CVD)
Cardiovascular disease (CVD), the leading cause of morbidity and mortality in the United States and
worldwide, causes substantial reductions in the quality of life, and accounts for significant health-related
expenditures (World Health Organization, 2014; Go et al., 2014). An estimated 17.5 million people die each year
from CVD, accounting for more than 30 percent of global deaths (American Heart Association, 2012). The total
cost of CVD in the United States (US) was estimated to be $320 billion dollars in 2012, including both direct
(healthcare related) and indirect (lost productivity) expenses (The American Heart Association, 2012).
CVD refers to a group of insidious pathological disease states that are defined by either: 1) a
weakening/abnormality of the heart or, 2) an inadequate blood supply to tissues/organ systems due to narrowing
of the aorta or aortic branches, peripheral arteries (peripheral vascular disease), cerebral vessels (stroke), or
coronary arteries (coronary heart disease) (The American Heart Association, 2012). Current treatment options for
CVD vary, but generally focus on reducing the work load on the heart by improving blood pressure/cardiac
function, or alleviating areas of restricted blood flow in the vasculature though pharmacological/surgical
procedures (Mahoney et al., 2010; Ouriel et al., 2001). Well-documented pathologies associated with increased
risk of the progression of CVD include, diabetes, hyperlipidemia, high blood pressure, arthritis, and obesity (Ford
and Mokdad, 2008; Cannon, 2007; Steinberg et al., 2008). The American Heart Association (AHA) and the
American College of Cardiology (ACC) assessed the frequency of comorbidities and the percentage of the
population of adults 65 years of age and older is shown in figure 1. The most common comorbid conditions for
three index cardiovascular conditions: ischemic heart disease, heart failure, and stroke, were hypertension,
hyperlipidemia, diabetes, and arthritis (Arnett et al., 2014). Furthermore, the prevalence of two or more chronic
conditions is estimated to be present in more than one quarter of US adults (Ward and Schiller et al., 2010).

1

Figure 1: The Most Common Comorbidities for CV Conditions in Adults 65 years of age and older: 2012
AHA/ACC/HHS Clinical Practice Guidelines
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As the global prevalence of these systemic pathologies continue to rise (Barbero et al., 2015), they are
becoming more frequently presented as comorbidities, representing an integrative disease state associated with
worsened health outcome (Kannan et al., 2008). Such a constellation of risk factors, specifically, abdominal
obesity, insulin resistance, elevated triglycerides, and low high-density lipoprotein cholesterol, is defined as the
metabolic syndrome (MetS). MetS is used to identify patients at high risk of CVD, type II diabetes, and overall
mortality (Alberti et al., 2009). It has been hypothesized that obesity is the defining pathology that contributes to
the evolution of MetS as well as some of the other components.
A critical effect of MetS is a reduction in the perfusion of blood flow to peripheral tissues that gradually
causes a decline in function and progressive loss of tissue viability, thereby severely impacting the ability to
exercise (Zhou Z et al., 2014). The failure to deliver and distribute blood to match metabolic demand is associated
with alterations in structure and compliance of the vasculature, and this also affects hemodynamic stress on the
heart as well as constrains functional hyperemia (Chantler and Frisbee, 2015). Functional hyperemia is defined as
an increase in tissue/organ system perfusion in response to metabolic demand. These effects could be caused by
mechanisms that alter vasodilator signaling, vasoconstrictor forces that compete with vasodilation, or structural
changes in vessel wall dynamics (Frisbee et al., 2009). However, structural alterations in the vasculature are not
2

always associated with CVD and both animal and human studies have demonstrated that vascular disease can
manifest in the absence of atherosclerotic plaques and lesions (Frisbee et al., 2011; Goodwill et al., 2009). Instead,
extensive evidence has demonstrated that maintenance of perfusion distribution and functional hyperemia is
dependent on endothelial function and adrenergic activity. Epidemiological studies have demonstrated that
endothelial dysfunction precedes any observable clinical sign of vascular disease and has been reported to predict
early subclinical stages of atherosclerotic disease (Grover-Páez and Zavalza-Gómez, 2009). This is clearly evident
in resistance arterioles of pre-hypertensive patients, which show impaired endothelial-dependent vascular
reactivity to dilator stimuli without visible structural changes far in advance of complications of hypertension, and
is also observed with aging, obesity, smoking, and other conditions in the absence of elevated blood pressure
(Schiffrin and Touyz, 2004). In fact, all of the underlying pathologies of MetS negatively impact the endothelium,
and impaired endothelium-dependent vasodilation of the brachial artery is observed in patients with MetS
(Chantler and Frisbee, 2015).
In addition, overactivity of the sympathetic nervous system has been implicated in virtually all CVD, and
subsequent adrenergic hyperactivity on vascular smooth muscle cells and endothelial cells increases vascular tone,
reduces vasodilation, and decreases blood flow (Zhou et al., 2014). It is clearly evident that any alteration to
vascular reactivity will greatly influence bulk flow of blood as well as regulation of blood pressure and peripheral
resistance (Hart et al., 2009). The consequential imbalance between endothelium-derived vasodilatation and
sympathetic activity under pathophysiological circumstances may cause vasoconstriction, leukocyte adherence,
platelet activation, thrombosis, impaired coagulation, vascular inflammation, pro-oxidation, and progression of
atherosclerosis. The role of endothelial dysfunction and adrenergic signaling will be addressed below.
Endothelial Dysfunction
Broadly speaking, endothelial dysfunction is defined as an impaired endothelial dependent vasodilator
response characterized by reduced nitric oxide (NO) bioavailability. This pathway is shown in figure 2. NO is
produced as a byproduct of catalytic conversion of NADPH and O2-dependent oxidation of l-arginine to lcitrulline mediated by eNOS. This pathway is activated by acetylcholine (ACh), bradykinin (B), and physical
forces (shear stress), as well as autacoids, prostaglandins, and platelet (serotonin and adenosine diphosphate) as
3

well as that cause eNOS to dimerize and sequester iron, enabling generation of high-affinity binding sites for
arginine and the cofactor tetrahydrobiopterin (BH4), which allow electron transfer from the reductase-domain
flavins to the oxygenase-domain heme (Zou et al., 2002). This reaction produces NO. NO rapidly diffuses into
adjacent smooth muscle cells, where it activates guanylyl cyclase – cGM pathway and induces vasodilation by
multiple mechanisms: inhibition of calcium entry into the cell and decrease intracellular calcium concentrations;
activation of K+ channels, which leads to hyperpolarization and relaxation; stimulation of a cGMP-dependent
protein kinase that activates myosin light chain phosphatase (Hart et al., 2011). Under normal conditions, NO is
one of the most potent vasodilators in the endothelium and is essential for maintaining normal homeostatic
balance within that vasculature, potentiating conditions of vasodilatation, low permeability, anticoagulation, and
inhibition of proinflammatory actions of leukocytes and platelets (Kelly et al., 2004).

Figure 2: NO Pathway in Endothelial Cells and Smooth Muscle Cells
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Endothelial dysfunction can be measured in different pathological conditions by vasodilator reactivity to
either pharmacological (e.g. infusion of endothelium-dependent agonists, such as acetylcholine) or physiological
(e.g. reactive hyperemia) challenge. A widely used clinical method employs flow mediated dilation (FMD), a
noninvasive in vivo measurement of endothelium-dependent vasodilation to shear stress in the brachial artery.
Numerous studies have demonstrated consistent reports of impaired FMD associated with endothelial dysfunction
and prognosis of CHD (Chan et al., 2003), untreated hypertension (Perticone et al., 2001), angina (Neunteufl et
al., 2000) PVD (Gokce et al., 2003) and chronic stress/depression (Sherwood, 2005). The most important
relationship that will be the focus of this dissertation is the bidirectional relationship between chronic
stress/depressive disorders and the development of CVD and CV risk factors.
CVD and Depression
The influence of psychological factors on the multifaceted pathophysiology of chronic diseases has been
an emerging field of behavioral cardiology (Mansura et al., 2015). Stress is a well-established trigger of mood
disorders, such as depression; stressful life events are one of the strongest predictors of onset and relapse, while
chronic stress exposure is associated with greater symptom severity and prevalence (Kim et al., 2007). Decades of
research investigating the relationship between chronic stress/depression and adverse CV events has established
that chronic stress/depression is a powerful risk factor for CVD morbidity and mortality and is also predictive of
more severe prognosis of cardiovascular events, including myocardial infarction (MI), coronary artery disease,
cardiomyopathies, and atherosclerosis (Rutledge et al., 2006; Pizzi et al., 2010). Furthermore, depression predicts
first CVD events even among otherwise healthy individuals, especially in women, and increases CVD incidence
1.5 to 6 fold (American Heart Association, 2011). Importantly this has been reported to be independent of
traditional CVD risk factors, including hypertension, insulin resistance, and total serum cholesterol (Penninx et
al., 2001).
Sex Differences
Sex disparity in the prevalence, clinical presentation and prognosis of both CVD and depression has
clearly been demonstrated in clinical and epidemiological studies (Hart et al., 2010). Premenopausal women have
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a lower incidence of CVD compared to age-matched men until approximately the age of menopause, at which
time a significant rise in the incidence of CVD events, as well as mortality rates, surpasses that of men (MollerLeimkuhler, 2007). In addition, classic CVD risk factors such as, hypertension, smoking, depression, and obesity,
also correlate more to overall CVD risk in women (Vaccarino et al., 1999; Bello et al., 2004; Kenachaiah et al.,
2004; Polk et al., 2005) compared to men. Surprisingly, pre-menopausal women are less likely to suffer from
CVD (Kessler et al 2003; 1993), but are concurrently two times as likely to be afflicted with depressive disorders
compared to men (Lloyd-Jones et al., 2010). This trend diminishes around the age of menopause as depression
incidence drops down to rates comparable to those of men. Current literature supports an association between
estrogen and the progression of depressive symptoms and comorbid diseases (Lloyd-Jones et al., 2010; Daniel et
al., 2005) relative to general CV protection and mechanisms related to NO processing and maintenance of
vascular homeostatic balance.
Unpredictable Chronic Mild Stress (UCMS)
Research opportunities that focus on specific mechanisms underlying the critical relationship between
chronic stress/depression and the progression of vascular disease have been greatly facilitated with the
emergence of translationally valid animal models. Several preclinical models of depression have been developed
over the past decade for use in behavioral research, theoretically based on the following parameters: similarity of
the model to the etiology and progression of clinical depression; ability of the model to recapitulate anatomical,
biochemical, neurophysiological, and behavioral features of human pathology; and similarity to the outcomes of
common interventions/treatments in humans (Strekalova et al., 2011). The most widely used preclinical models
of depression in behavioral research include the learned helplessness model (Porset, 2005), the early life stress
model (Willner, 1997), the social defeat model (Grippo, 2005), and the unpredictable chronic mild stress
(UCMS) model (Isingrini et al., 2012). Learned helplessness is a paradigm based on the observation that animals
develop deficits in motivation, cognitive and reward behaviors following repeated unavoidable and
uncontrollable shocks. Models of early life stress involve prenatal stress, early postnatal handling and maternal
separation, and have been beneficial in studies of chronic stress-induced effects on epigenetics and early life
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development. The social defeat stress model is designed to create a state of submission and anxiety in an inferior
animal via imposition of a physically superior aggressive animal.
The model used for the experiments of this dissertation is the unpredictable Chronic Mild Stress (UCMS)
model. The UCMS model involves repeated and randomized exposure of daily mild stressors, causing gradually
progress to a cumulative stress response. In these means, animals are exposed to randomized mild environmental
and social stressors each day for 8 weeks (Willner, 1997). A crucial distinguishing factor that enhances the
translational relevance of this model to chronic stress in humans lies in the high degree of unpredictability and
uncontrollability of the stressors encountered over an extended period, without imposing life-threatening or
severe challenges on the animals. The UCMS model relies on the fundamental concept that chronic exposure to
unpredictable, exogenous stressors ultimately leads to the development of depressive symptoms similar to that of
clinical depression, including decreased responsiveness to rewards (anhedonia), changes in physical activity and
investigative behavior (helplessness and despair), deterioration of the coat state and altered sexual activity
(Willner, 1997). Furthermore, variable behavioral outcomes in rodents have been reported in UCMS studies. For
example, a stress resilient phenotype that largely prevents depressive-like behavior changes following UCMS can
develop, indicating differences in stress susceptibility (Bouzinova et al., 2012). Additionally, altered depressive
behaviors can gradually be reversed by chronic, but not acute, treatment with certain antidepressants,
demonstrating similar neurological effects of antidepressants in depressed patients. Lastly, this model is most
fitting for this dissertation based on observations showing UCMS-induced depressive symptom severity in
rodents is a powerful, independent predictor of endothelium-dependent vasomotor responses to pharmacological
stimuli in aortic rings and peripheral arteries (Stanley et al., 2014; d’Audiffret et al., 2010). Specifically, the
attenuated endothelial dependent vasodilator reactivity is associated with similar outcomes observed in patients
with depression, including decreased NO bioavailability (Chrapko et al., 2004), and increased levels of
circulating biomarkers for cellular adhesion, inflammation, and thrombosis (Rajagopalan et al., 2001;
Dimopoulos et al., 2006). In addition, sex specific differences in outcomes following UCMS are observed,
further increasing the value of this method for investigating sex disparity in chronic stress/depressive disorders
and CVD pathology. Therefore, this dissertation will focus on mechanisms linking chronic stress/depression and
7

the evolution of CVD and related vascular diseases, specifically those involved in compromising functional
hyperemia and vascular reactivity.
Sympathetic-Adrenal-Medullay (SAM) Axis
The adrenergic system has been the focus of many research investigations into the pathogenesis of
chronic stress/depression and CVD (Antonijevic, 2006). Hyperactivity of SAM axis is observed in depressed
patients and persistent noradrenergic activity has been linked with negative outcomes in patients with CVD and
CVD risk factors, including congestive heart failure (Francis et al., 1993) and diabetes (Ganguly et al., 1986).
Most of these effects are initiated by SAM-induced release of catacholamines, norepinephrine (NE) and
epinephrine (Epi). Central NE influence alertness, arousal, and reward systems; enhances corticotropin-releasing
hormone (CRH) release from the hypothalamus; and promotes sympathetic activity while attenuating vagal
innervation. In the periphery, the adrenergic system innervates vascular smooth muscle cells and endothelial cells,
strongly impacting vascular reactivity (Schreihofer et al., 2005; Frisbee, 2006; Esler, 2001). Any such alteration
will greatly influence regional blood flow as well as regulation of blood pressure, vasomotor tone, and peripheral
resistance (Hart et al., 2009). Studies in the OZR have confirmed that pre-existing CVD risk factor is associated
with increased vasoconstrictor reactivity in response to adrenergic stimuli in both skeletal muscle and renal
circulation (Naik et al., 2006) while intravenous infusion of α-adrenoreceptor antagonists eliminated differences
in arterial pressure in OZRs and significantly increased perfusion through these vascular networks compared to
their lean controls. Together, these data suggest increased adrenergic response in a MetS model alters blood flow.
In recent years, several studies have demonstrated that sex-specific mechanisms moderate sympathetic
neural and vascular control in humans. For example, estrogen binding to endothelial membrane estrogen receptors
causes the release of NO from the endothelium (Duckles & Miller, 2010), opposing the vasoconstrictor effects of
sympathetic stimulation. Data previously published demonstrated an increase in vasoconstriction to phenylephrine
in arteriolar vessels of male mice subjected to UCMS, while a similar vasoconstrictor response was observed in
UCMS females only after inhibition of NOS activity with L-NAME (Stanley et al., 2014). This suggests that
modulation of adrenergic vascular reactivity by endogenous NO under non-stressed conditions remains largely
intact in females despite UCMS, but is diminished in males. The loss of NO actions on attenuating adrenergic
8

sensitivity in conditions of chronic stress and reduced NO bioavailability (Hart et al., 2009; Puzserova et al.,
2012) may be an underlying reason for coordination between mental stress- induced sympathetic activity and
systemic peripheral resistance in young men, but not women (Hart et al., 2009). Furthermore, studies have
demonstrated that women exhibit a blunted transduction of muscle sympathetic nerve activity (MSNA) into limb
vascular tone following psychological stress, while men were more sensitive to the vasoconstrictor action of
MSNA during the same stress challenge (Yang et al., 2013). Differences in neural-vascular coupling have been
linked to adrenergic receptor sensitivity/density as well as effects of estrogen on NO bioavailability (Hart et al.,
2009).
Hypothalamic-Pituitary-Adrenal (HPA) Axis
The glucocorticoid hypothesis has been repeatedly implicated in pathophysiological mechanisms of
depression in both human and animal studies (de Kloet et al., 1998, 2005).

Stress stimulates the HPA axis

neuroendocrine pathway beginning with the release of corticotrophin-releasing hormone (CRH) from the
hypothalamic paraventricular nucleus (PVN), causing adrenocorticotropic hormone (ACTH) secretion from the
anterior pituitary and subsequent interaction at the adrenal medulla and lead to the release of glucocorticoid (GC)
into circulation. The main GC in humans is cortisol, while in rodents, it is corticosterone. The stress response is
turned off by GC feedback at GC receptors (GR) and mineralocorticoid receptors (MR) at the brain and pituitary
sites. However, chronic stress- induced activation of the HPA axis impairs the negative regulatory mechanisms of
these peripheral/central receptors (Pariante et al., 2001; Sapolsky et al., 2000). Subsequent hypercortisolemia,
(measured in the plasma, urine, and cerebrospinal fluid (CSF) (Burke et al., 2005) is one of the most common
clinical observations in depressed patients (de Kloet et al., 2005), resulting in systemic vascular and metabolic
effects. GCs can directly and indirectly contribute to vasoconstrictive responses and endothelial dysfunction. GCs
directly cause endothelial alterations that decrease NO bioavailability by limiting tetrahydrobiopterin (BH 4) activity
and eNOS gene transcription as well as increasing the production of ROS. Further, proinflammatory cytokines
disrupt GC receptor function on immune cells via activation of NF-kB, p38MAPK and the 5-STATS pathways,
which inhibits expression of the active receptor (Roy and Campbell, 2013) and accelerates low-grade, chronic
inflammation (Roy and Campbell, 2013; Rohleder, 2012). Concurrently, GC receptor function is reportedly reduced
9

in lymphocytes of depressed patients (Rohleder, 2012), thus failing to attenuate immune responses (Roy and
Campbell, 2013). In addition, permissive functions of GCs enhance the vascular vasoconstrictor responses of other
stress-associated hormones, such as catacholamines and angiotensin II via upregulation of their receptor expression
in vascular smooth muscle cells (Ullian and Walsh, 1995). Together, these processes can damage vascular
endothelium and impair endothelial dependent vasoreactivity. This is supported by studies that have found treatment
with GC synthesis inhibitor improves endothelial dysfunction in depressed patients (Young and Ribiero, 2006).
Inflammation
Some researchers have claimed that inflammatory events are the initial underlying cause of chronic
stress/depression and CVD related factors (Manabe, 2011). Patients with depression exhibit elevated plasma levels
of inflammatory markers, including prostaglandin E2 (PGE2), CRP, TNF-α, IL-1β, IL-2 and IL-6, in the peripheral
plasma and CSF. TNFα and IL-6 impact both endothelial function and glucose metabolism, and have been linked to
insulin resistance via autophosphorylation of insulin receptor substrate-1 (Hotamisligil et al., 1996).

TNFα

stimulates nuclear transcription factor-kappa B (NF-kB), a critical mediator of inflammatory responses, apoptosis,
and expression of growth factors, proinflammatory cytokines and adhesion molecules, such as MCP-1, which is
involved in macrophage recruitment (Knight and Imig, 2007). IL-6 is the primary regulator of C-reactive protein
(CRP), and thus, increases CRP-mediated activity within the vasculature, resulting in inhibition of eNOS, elevated
expression of adhesion molecules, and angiotensin-stimulated ROS production (Singer and Granger, 2007). These
data demonstrate that one factor can contribute to vasculopathies via multiple mechanisms.
Animal models of chronic stress/depression have shown increased protein levels of TNFα, CRP, MCP-1,
and expression of intercellular adhesion molecule 1 (I-CAM1) (Lu et al., 2013). However, reports regarding
inflammatory markers in chronic stress/depression and related pathology have proven to be largely inconsistent and
difficult to replicate experimentally. This has been confirmed by previous studies indicating the multifaceted
relationship and complex components of chronic stress/depression pathology. The relevance of individual vascular
inflammatory markers and CV risk factors measured in vessels of UCMS mice was based on the specific disease
conditions as well as the individual developmental route by which chronic stress influenced vascular pathologic
events/outcomes (d’Audifffret et al., 2010). Division of the vascular outcomes into tertiles based on severity
10

improved correlative values with specific risk biomarkers, but the variability in individual UCMS animals was still
great. Data presented in Figure 3 shows the correlation between a given tertile of vascular impairment severity and
specific CVD risk factors. These data demonstrate that aggregate measures of insulin resistance, inflammation, and
hypertension are not robust predictors of vascular dysfunction, and unidentified mechanisms may be involved in
heterogeneous outcomes between (d’Audifrett et al., 2010) individual inbred rodents. Human studies also reflect
substantial heterogeneity in response to stress along with marked disparities in the pathophysiological outcome of
depressive symptoms on comorbid diseases (Brosse et al., 2002).

Figure 3: Correlations between vascular reactivity and individual CVD risk factors in control and UCMS
mice following separation of the lower bound of the methacholine concentration-response curves into tertiles
based on the severity of impairment in dilator responses.
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Oxidative stress
Reactive Oxygen Species (ROS) are short lived, highly reactive derivatives of oxygen metabolism involved
with many normal biochemical processes in non-disease conditions. However, increased ROS production can
overwhelm the endogenous antioxidant capacity of the system and cause deleterious damages that oxidize lipids,
denature the function/structure of protein and DNA and activate redox-sensitive transcription factors and signal
transduction pathways. In addition, ROS can interact with various cell receptors to down-regulate the production of
antioxidants, such as superoxide dismutase (SOD), Glutathione, and catalase, further disrupting the oxidative/antioxidative balance in favor of unchecked ROS production. Primary sources of vascular oxidant stress are the
NADPH oxidase family, xanthine/xanthine oxidase, uncoupled eNOS, cyclooxygenase, lipoxygenase, and
cytochrome P450, as well as disrupted mitochondrial electron transport system (Figure 4).

Figure 4: Sources of ROS
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In pre-clinical animal models of hypertension and diabetes, oxidative stress and impaired endothelial
function have been attributed to reduced bioavailability of NO and shown to increase production of superoxide
anion, one of the most reactive oxygen radicals (Davis and Zou, 2005). These pathways are shown in Figure 5.
Superoxide (·O2-) can interact with NO to form the potent compound peroxynitrite (·ONOO-), which in turn readily
induces uncoupling of eNOS, via oxidizing cofactor BH4, thus having a twofold impact: scavenging NO as well as
inhibiting the activity of eNOS (Goodwill and Frisbee, 2012). Peroxynitrite also is involved in inactivating
prostacyclin synthase (Davis and Zou, 2005). Oxidative stress is increased in UCMS animals and impaired
vasodilator responses in the aortic rings and GAs was reversed with SOD mimetic treatment. However, treatment
with a combination of TEMPOL and eNOS inhibitor abolished the effects of TEMPOL alone in UCMS male mice,
suggesting that uncoupling of eNOS was contributing largely to endothelial dysfunction (Stanley et al., 2014).
Further studies have demonstrated that increased superoxide production within the vasculature was associated with
endothelial vasomotor dysfunction, which was reversed by the administration of agents capable of scavenging
superoxide, such as vitamin C (Heitzer et al., 2001). These findings suggest that increased oxidative stress may be
an important mechanism that impairs endothelial function in patients with atherosclerosis or cardiovascular risk
factors, as well as in patients with chronic stress/depression.
Oxidative stress can alter the balance between circulating vasodilatory and vasoconstrictive factors, thereby
changing a major regulatory component of vasoactivity and vascular tone (Goodwill et al., 2008). A wellestablished example is the role of arachidonic acid (AA) metabolism and COX pathway. The membrane-bound
lipid, AA, is freed following cleavage by a phospholipase, enabling AA to diffuse into the cytoplasm of the cell
where it can be metabolized by three different cytosolic enzymatic pathways: cyclooxygenase (COX), cytochrome
P-450, and lipoxygenase. The COX pathway catalyzes the intermediate prostaglandin H 2 into opposing vasoactive
compounds, namely PGI2 via prostacyclin synthase, or TXA2 via thromboxane synthase. PGI2 increases vasodilation
by a second messenger cyclic adenosine monophosphate (cAMP) signaling pathway and has similar, but less
profound, effects within the vasculature compared to NO (Ledoux et al., 2006). Conversely, thromboxane mediates
platelet activation, endothelial cell activation, vasoconstriction, and smooth muscle cell proliferation (Traupe et al.,
2002). Recent reports demonstrated that production of TxA2 is increased while PGI2 is decreased in an animal
13

model of MetS, significantly impacting vascular tone and severity of adrenergic constriction (Goodwill et al., 2008).
Further, clinical studies have shown that patients with CVD have increased propensity to generate TXA 2, more
activate thromboxane receptors, and blunted platelet-mediated vasodilatation (Traupe et al., 2002). A shift in the
production of COX metabolites favoring vasoconstriction has been implicated in disease states such as
hypertension, CAD, diabetes, and depression.

Figure 5: Pathways of ROS Production in the Vascular Endothelium
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Endothelium produces a less well-characterized compound known as endothelial dependent hyperpolarizing
factor (EDHF) that promotes vascular smooth muscle relaxation and vasodilation. The exact contributing factors
making up EDHF metabolites are unclear, but hydrogen peroxide (H2O2) has been indicated. H2O2 is the product of
SOD mediated reaction of water and superoxide. In a previous study, UCMS induced impairments to vasodilator
responses to methacholine were more severely blunted following inhibition of H2O2 with catalase in aortic rings
compared to controls (d’Audiffret et al., 2010), suggesting the promotion of a compensatory mechanism when NO
levels are reduced. This is shown in Figures 6A and 6B.
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Figure 6: Dilator responses of aortic rings to increasing concentrations of methacholine in control and UCMS
mice.

*P < 0.05 vs. responses in untreated vascular rings from control mice; †P < 0.05 vs. responses
in untreated vascular rings from UCMS mice; n = 8 for control; n = 8–9 for UCMS.

There have been reports showing differences in the induction of the oxidative response between the sexes.
Specifically, a relationship has been reported between estrogen and general cardiovascular protection and
antioxidant defense that reduce reactive oxygen species and thereby increase NO bioactivity (Kamper et al., 2009;
MacRitchie et al., 1997). The antioxidant effects of estrogen have been reported to occur through genomic as well
nongenomic alterations (Gomez-Zubeldia et al., 2000; Borras et al., 2005) while testosterone has been shown to
decrease antioxidant (superoxide dismutase, glutathione peroxidase) activity (Chainy et al., 1997).
Clinical Significance
Depression imparts a serious deleterious effect on chronic medical conditions, with potentially adverse
influences on self-care (e.g., adherence to diet, exercise, cessation of smoking, use of medication), disease control,
symptom burden, development of medical complications, quality of life, and the cost of healthcare. Similarly,
chronic medical conditions, especially one as tightly linked to stress-related events as CVD, are affectively
stressful for patients and may influence pathophysiologic mechanisms as well as mood related to depression.
Depression imparts a serious deleterious effect on chronic medical conditions, with potentially adverse influences
on self-care (e.g., adherence to diet, exercise, tobacco use, medical compliance), disease control, symptom
15

burden, development of medical complications, quality of life, and the cost of healthcare. Thus, understanding the
bidirectional relation between depression and comorbid CVD is an essential goal in order to ensure optimal health
care.
Furthermore, the marked sex disparity in depression risk and CVD development warrants further investigation
to improve clinical healthcare; however, the precise sex-specific mechanisms regulating cardiovascular
physiology and neurological function are largely unclear. An emergent area of research has focused on identifying
functional pathways and mechanisms of sex hormones on processes of stress reactivity with the ultimate goal of
understanding the divergent pathophysiologies of depression between males and females. Basic sex differences in
homeostasis and autonomic signaling begin early in development and continue throughout adulthood, and
resulting hormonal and neuroendocrine differences profoundly impact not only normal physiology, but also the
pathways that link the stress response with susceptibilities to depression and comorbid CVD. Interrogation of the
sex-specific mechanisms defining this link may lead to improvements in disease progression and prognosis for
both men and women and facilitate development of more effective therapeutics and interventions that target sexspecific pathophysiological mechanisms of CVD development.
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ABSTRACT
The presence of chronic, unresolvable stresses leads to negative health outcomes, including development
of clinical depression/depressive disorders, with outcome severity being correlated to depressive symptom
severity. One of the major outcomes associated with chronic stress and depression is the development of
cardiovascular disease (CVD) and an elevated CVD risk profile. However, in epidemiological research, sex
disparities are evident, with pre-menopausal females suffering from depressive symptoms more acutely than
males, but also demonstrating a relative protection from the onset of CVD. Given this, we investigated the
differential effect of sex on conduit artery and resistance arteriolar function in male and female mice following
eight weeks of an unpredictable chronic mild stress (UCMS) protocol. In males, plasma cortisol and depressive
symptom severity (e.g., coat status, anhedonia, delayed grooming) were elevated by UCMS. Endotheliumdependent dilation to methacholine/acetylcholine was impaired in conduit arteries and skeletal muscle arterioles,
suggesting a severe loss of NO bioavailability and increased production of TxA 2 versus PGI2 associated with
elevated reactive oxygen species and an increased level of systemic inflammation. Endothelium-independent
dilation was intact. In females, depressive symptoms and plasma cortisol increases were more severe than in
males, although alterations to vascular reactivity were blunted, including the effects of elevated ROS and
inflammation on dilator responses. These results suggest that, in comparison to males, female rats are more
susceptible to chronic stress in terms of the severity of depressive behaviors, but that the subsequent development
of vasculopathy is blunted owing to an improved ability to tolerate elevated ROS and systemic inflammatory
stress.

Key Words:

vasodilation, endothelium-derived factors, peripheral vascular disease, nitric oxide, models of

chronic stress, clinical depression
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INTRODUCTION
During the last decade, extensive evidence from epidemiologic and clinical studies has identified a
complex relationship between depressive disorders and cardiovascular disease (CVD) outcomes (34, 41, 44, 45,
58). Depression is a powerful risk factor for development of CVD, and can be a predictor of cardiovascular
pathologies, including myocardial infarction, coronary artery disease, and cardiomyopathies, regardless of prior
history of overt CVD (41,44).
A consistent body of evidence indicates that chronic stress, a major contributor to depressive illnesses,
may be a potent pathogenic factor linking depression and CVD, in part due to the stress-induced activation of the
sympathetic-adrenalmedullary and hypothalamic pituitary adrenal (HPA) axes (1, 2, 4, 7, 9, 47). Dysregulation of
these two essential systems has been linked to depression and the development of several CVD risk factors,
including sex-specific pathophysiological factors associated with autonomic nervous and immune dysfunction,
and alterations to vascular reactivity and endothelial function (20, 22, 49. 56). Compared to age-matched male
counterparts, pre-menopausal women are at lower risk of developing CVD (29, 30), but concurrently are twice as
likely to suffer from depressive disorders (28, 35). This trend diminishes at menopause and risk of CVD and
neuropsychological disorders in women rapidly increases (32, 35). Current literature supports an association
between estrogen and the progression of depressive symptoms and comorbid diseases (17, 35, 55), but also a
relationship between estrogen and general CV protection and antioxidant defense (6, 27, 37).
We (12, 14, 26. 42), and others (3, 5, 27, 39) have previously reported that the impact of chronic stress
and depression on aortic ring reactivity is mediated through altered endothelial dysfunction, characterized by an
impaired dilator metabolite bioavailability.

A comparable outcome, including poor endothelium-dependent

reactivity (14, 25, 26, 36), nitric oxide bioavailability (42, 48), as well as a pro-inflammatory (24, 36, 39) and prothrombotic (43) environment, has also been observed in depressed human patients, and represents and an
independent predictor of risk for the development of CVD (18, 48). As circulating levels of estrogen also exert a
positive impact on processes associated with vascular function (6, 27, 35, 37), the impact of sex on CVD under
conditions of chronic stress and depression is an area that warrants investigation.
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The unpredictable chronic mild stress (UCMS) procedure is a widely used animal model of induced
depressive symptoms and has been well-established in behavioral studies as an extremely relevant rodent model
of human depression based upon its ability to reproduce clinical symptoms of depression, including anhedonia
and learned helplessness (25, 46, 59). Studies utilizing the UCMS protocol have reported increased behavioral
vulnerability to UCMS in female rodents (23, 32, 45) associated with increased cortisol levels (15, 16), altered
estrous cycle (15, 16, 23, 31), and decreased serotonergic and dopaminergic turnover ratios in brain regions
related to stress and depression (16, 33). However, compared to male counterparts, UCMS female rodents show
greater antioxidant defense and increased NO bioavailability, helping to maintain normal endothelial function and
enhanced vascular anti-inflammatory and antioxidant capacities (27, 50).
The purpose of this study was to determine the differential susceptibility to depressive symptom
development following UCMS between male and female mice, and to elucidate sex-specific mechanisms
underlying vascular/endothelial dysfunction in both conduit vascular rings and in pressurized resistance arterioles.
This study tested the hypothesis that 8 weeks of UCMS will result in a more severe development of depressive
symptoms in female mice (versus males), but that vascular function will be preserved to a superior extent than in
males.

Of special note, this study utilized a protocol wherein the estrous cycle of the female mice was not

matched. Rather female mice were randomized throughout their cycle to get a better assessment of a true sex
difference rather than one that reflects cyclic variations in hormonal status.

MATERIALS AND METHODS
Animals: Male and female BALB/cJ mice (Jackson) were fed standard chow and drinking water ad libitum and
were housed in the animal care facility at the WVU HSC. All protocols received prior IACUC approval. At nine
weeks of age, mice from each sex were divided into two groups, control and UCMS (below). After eight weeks
duration under either condition, mice were anesthetized with injections of sodium pentobarbital (50 mgkg-1 i.p.) and
a carotid artery was cannulated for determination of arterial pressure. Venous blood aliquots were collected for
biochemical evaluation of plasma biomarkers of treatment outcomes and health status of the mice.
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Unpredictable Chronic Mild Stress Protocol: All mice were doubly housed, with the control group in a separate quiet
room in close proximity to the room used for UCMS treatments. Alternatively, in the UCMS group, mice were
randomly exposed to the following stressors on multiple occasions throughout each 24 hour period:
1. Damp bedding – 10 oz. of water was added to each standard cage for the next 3 hours
2. Water – all bedding was removed and ~0.5 inches of water was added to empty cage for the next 3 hours.
Water temperature was ~30°C and the room temperature was ~24°C
3. Each cage was tilted to 45 degrees with or without bedding for 3 hours
4. Social stress – each mouse was switched into a cage of a neighboring mouse for 3 hours
5. No bedding lasting for 3 hours or, on two occasions each week, overnight.
6. Succession of light/dark cycles, lasting 30 minutes throughout a 24 hour period
7. Exposure to predator smells (e.g., cat fur) and/or sounds (e.g., cat growling) for 8 hours
After eight weeks, all mice were subjected to a series of behavioral tests to evaluate the outcomes of the
UCMS procedures.
Coat Status: This evaluation was done throughout the duration of the UCMS protocol. The total cumulative score
was computed by giving an individual score of 0 (clean) or 1 (dirty) to eight body parts (head, neck, dorsal coat,
ventral coat, tail, forelimb, hind-limb, and genital region).
Splash Test: This test was used to evaluate acute grooming behavior, defined as cleaning of the fur by licking or
scratching. A 10% sucrose solution was sprayed on the dorsal coat of each mouse and grooming activity was
recorded for five minutes. The viscosity of the sucrose solution will dirty the coat and induce grooming behavior, with
depressive symptoms characterized by an increased latency (idle time between spray and initiation of grooming)
and decreased frequency (number of times grooming a particular body part).
Tail Suspension Test: Mice subjected to the short term, inescapable stress of tail suspension, will develop an
immobile posture, with longer periods of immobility in mice exhibiting a depressed behavior. Mice were completely
suspended by the tail on a horizontal bar 35 cm from the base platform using adhesive tape such that contact with the
laboratory benchtop was not possible. The latency to the first bout of immobility and the duration of total immobility
were recorded for six minutes.
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Measurements of Vascular Reactivity (Skeletal Muscle Resistance Arterioles): From each anesthetized mouse,
the intramuscular continuation of the gracilis artery was removed and cannulated, as described previously (8).
These first order arterioles were extended to their approximate in situ length and were equilibrated at 80% of
mean arterial pressure in order to approximate in vivo intralumenal pressure. Following equilibration, the
reactivity of isolated, pressurized arterioles was assessed in response to increasing concentrations of phenylephrine
(10-10 M – 10-7 M) to assess adrenergic constrictor responses and increasing concentrations of acetylcholine (10-10 M –
10-6 M) and sodium nitroprusside (10-10 M – 10-6 M) to assess dilator reactivity. Vascular responses to stimuli were
also determined following treatment with L-NAME (10-4 M), indomethacin (10-5 M) and TEMPOL (10-4 M) for 4560 minutes, to assess the roles of nitric oxide, cyclooxygenase and reactive oxidant stress, respectively, in modulating
reactivity.
Measurements of Vascular Reactivity (Conduit Arteries): Following removal of the resistance arteriole in each
mouse, the thoracic aorta was removed, rinsed in physiological salt solution, cleared of surrounding tissue, and cut in
2-3 mm ring segments. Each ring was mounted in a myobath chamber between a fixed point and a force transducer
(World Precision Instruments), and set to 0.5 g tension for 45 minutes to equilibrate. The organ baths contained
physiological salt solution at 37ºC, and aerated with 95% O2 and 5% CO2. Rings were pre-conditioned by treatment
with 10-7 M phenylephrine for 5 minutes, at which time 10-5 M methacholine was added to the bath to assess
endothelial integrity. Any ring that failed to demonstrate both a brisk constrictor response to phenylephrine and
viable endothelial function was discarded. Subsequently, rings were treated with increasing concentrations of
phenylephrine (10-10 M – 10-4 M) to assess constrictor reactivity. For the assessment of dilator reactivity, rings were
pre-treated with 10-6 M phenylephrine and exposed to increasing concentrations of methacholine (10-10 M – 10-4 M)
and sodium nitroprusside (10-10 M – 10-4 M). To assess the roles of nitric oxide, cyclooxygenase and reactive oxidant
stress in modulating vascular responses to the agonist treatments, concentration-response curves were also conducted
following pre-treatment of the rings for 45-60 minutes with L-NAME (10-4 M), indomethacin (10-5 M) and TEMPOL
(10-4 M), respectively.
Measurement of Vasoactive Metabolite Bioavailability: From mice within each group, the remaining sections of
the thoracic and abdominal aorta that were not used for measurements of reactivity were used to assess vascular
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NO, PGI2 (from levels of 6-keto-PGF1) and TxA2 (from levels of 11-dehydro-TxB2) bioavailability using
amperometric sensors (World Precision Instruments) and a commercially available kits (Cayman), respectively.
Briefly, aortae were isolated, cleaned, sectioned into ~1 mm lengths and placed within a chamber filled with
physiological salt solution equilibrated with 21% O2, 5% CO2, balance N2. Within this chamber, a nitric oxide
sensor (ISO-NOPF 100) was inserted and a baseline current was obtained. Subsequently, methacholine (10-8, 106

, and 10-4 M) was added to the chamber and the changes in current were determined. To verify that responses

represented NO release, these procedures were repeated following addition of L-NAME (10-4 M) to the chamber.
In response to challenge with 10-4 M methacholine, an aliquot of PSS was removed from the chamber and used
for determination of PGI2 and TxA2 production.
Biochemical Analyses: In all samples, fasting blood glucose (8 hour) was determined using a commercially available
glucometer (Freestyle). Chronic oxidant stress was assessed through determination of plasma nitrotyrosine and
plasma cortisol was determined using standard kits (Cayman). Finally, using a multiplexed procedure, plasma insulin
and biomarkers of inflammation were assessed using commercially available kits (Millipore).
Data and Statistical Analyses: Mechanical responses following challenge with methacholine or phenylephrine were
fit with the three-parameter logistic equation:

 max  min 
y  min  
log ED x
1  10 50 
where y represents the isometric tension, “min” and “max” represent the lower (minimum) and upper (maximum)
bounds, respectively, of the change in tone with agonist concentration, x is the logarithm of the agonist concentration
and

log ED50

the bounds.

represents the logarithm of the agonist concentration ( x ) where the response ( y ) is halfway between
The use of the three-parameter logistic equation is appropriate for the analysis of sigmoidal

concentration-response relationships, as it simultaneously provides estimates of the curve maximum (upper bound),
minimum (lower bound) and the dose at which the dependent variable reaches 50% of maximum (ED50). In the case
of a dilator response where the initial condition is set to 100% (the upper bound), the asymptotic minimum (the
lower bound from the equation) is reflective of the degree of dilator reactivity for that vessel. If the vessel
becomes “more reactive”, the lower bound will decrease toward reduced levels, while if the vessel becomes less
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reactive, the lower bound will increase toward higher values. This situation is reversed for constrictor responses,
where the vessel starts at the lower bound, and then goes through a range of increased tensions to reach an upper
bound/asymptotic maximum.

For the presentation of results, we have focused on the changes in the upper or

lower bounds, as we did not determine a consistent or significant change to the ED50 values between relevant
experiment groups.
All data are presented as mean±SEM. Significant differences between groups were determined using
analysis of variance (ANOVA). In all cases, Student-Newman-Keuls post hoc test was used when appropriate and
p<0.05 was taken to reflect statistical significance.

RESULTS
Table 1 presents data describing the characteristics of mouse groups in the present study. At the time of final
use, plasma insulin and nitrotyrosine were significantly greater in UCMS mice than in controls. No consistent and
significant differences were determined between body mass, mean arterial pressure and blood glucose between
conditions or sex. Plasma levels of cortisol were significantly increased with UCMS in both sexes as compared to
controls, and levels in UCMS-females were significantly greater than that in UCMS-males.
The impact of the UCMS protocol on depressive behaviors in mice is summarized in Figure 1. Throughout 8
weeks of UCMS, the coat status in mice undergoing the stress protocol was consistently poorer compared to that in
control animals (Panel A), although the severity of this degradation in coat status was significantly worse in UCMSfemales. In response to the sucrose spray, control mice demonstrated both a more rapid (Panel B) and a more
frequent (Panel C) grooming response as compared to that exhibited by mice of either sex following the UCMS
protocol. However, the latency of the grooming response was greater in UCMS-females as compared to that in
UCMS-males. Panel D presents the total period of immobility in response to tail suspension, where control mice
demonstrated a significantly shorter period of immobility as compared to that in UCMS mice of either sex.
Consistent with the previous measurements, UCMS-females demonstrated a longer period of immobility as compared
to UCMS-males.
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The constrictor responses of aortic rings from control and UCMS-mice in response to increasing
concentrations of phenylephrine are summarized in Figure 2. As compared to responses in aortic rings from control
mice, rings from UCMS-males exhibited a similar constrictor response to the adrenergic agonist (Panel A). In
contrast, the constrictor response of aortic rings from UCMS-females was not different from that in controls.
Following pre-treatment of vessels from all groups with L-NAME, responses of aortic rings from the control and
UCMS groups remained similar in response to increasing concentrations of phenylephrine (Panel B). Pre-treatment
of aortic rings with indomethacin did not significantly alter responses to phenylephrine from that determined under
untreated conditions in any group (data not shown).
A summary of the methacholine-induced dilator responses of aortic rings from control and UCMS-mice is
presented in Figure 3. In comparison to responses from control mice, the dilation to increasing concentrations of
methacholine was significantly reduced in both male and female UCMS mice, although the severity of this blunted
response was greater in the aortic rings from UCMS-males (Panel A). In aortic rings from control animals, pretreatment with either L-NAME or indomethacin resulted in a significant inhibition of methacholine-induced dilator
reactivity, while pre-treatment with both nearly abolished all responses to the agonist (Panels B and C). In aortic rings
from UCMS-males, pre-treatment with L-NAME did not further impact the reduced dilator responses to
methacholine, although treatment with indomethacin reduced dilator responses from the untreated condition (Panel
D). In conduit artery segments from UCMS-female rats, treatment with L-NAME reduced methacholine-induced
dilation, while responses following treatment with indomethacin were less striking (Panel E). In all cases, combined
treatment with both L-NAME and indomethacin nearly abolished the reactivity of aortic rings to increasing
concentrations of methacholine.
Figure 4 summarizes the responses of aortic rings from control and UCMS-mice to increasing concentrations
of sodium nitroprusside. In all cases, application of the nitric oxide donor resulted in a significant dilator response
that was not different between control and UCMS-mice of either sex.
The production of dilator metabolites in response to methacholine challenge is presented in Figure 5.
Vascular production of nitric oxide following application of methacholine was significantly reduced in conduit
arteries of UCMS-mice of either sex, although the severity of this reduction was greater in UCMS-males (Panel A).
34

A similar pattern was determined for the vascular production of PGI2, with the methacholine-induced production of
this metabolite, estimated from 6-keto-PGF1, being reduced in UCMS mice of both sexes (male>female) as
compared to responses in arteries from control mice (Panel B). Vascular production of TxA2 (Panel C) was low and
similar in male and female mice under control conditions. In response to the UCMS protocol, the vascular production
of TxA2 was significantly elevated in both sexes, but was significantly increased in UCMS males as compared to
UCMS females.
The impact of pre-treatment of aortic rings with the antioxidant TEMPOL on vascular production of nitric
oxide following methacholine challenge is presented in Figure 6. While bioavailability of nitric oxide was attenuated
in vessels from both male and female mice following UCMS treatment (males>females), pre-treatment of vessels
with TEMPOL significantly increased the bioavailability of nitric oxide in vessels from UCMS-males. While a trend
for this was evident in UCMS-females, this effect was not as striking, likely owing to the more modest reductions in
NO bioavailability as a result of the UCMS protocol itself in these mice. Treatment of vessels with L-NAME
abolished methacholine-induced NO bioavailability in all conditions.
The effects of pre-treatment of aortic rings from UCMS-mice with TEMPOL on dilator responses are
summarized in Figure 7. In aortic rings from both UCMS-male (Panel A) and UCMS-female (Panel B) mice, pretreatment with TEMPOL significantly increased dilator responses to methacholine from the untreated responses;
subsequent treatment of vessels with L-NAME or indomethacin significantly reduced dilation from this improved
level of reactivity.
The constrictor responses of isolated skeletal muscle (gracilis) arterioles in response to increasing
concentrations of phenylephrine are summarized in Figure 8. In arterioles from male rats, imposition of the UCMS
protocol resulted in a significant increase in the vasoconstrictor responses to phenylephrine as compared to responses
in vessels from control animals (Panel A). Pre-treatment of vessels with L-NAME abolished all differences in
phenylephrine-induced constriction between sexes and treatment condition (Panel B).
Figure 9 presents the dilator responses of gracilis muscle arterioles from control and UCMS-treated mice in
response to increasing concentrations of acetylcholine. In males, UCMS treatment blunted dilator responses to
acetylcholine from levels in controls; pretreatment of vessels from UCMS-males with L-NAME had no effect on
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reactivity, while pretreatment with indomethacin further blunted this impaired response (Panel A). However,
treatment of arterioles from UCMS-males with TEMPOL was very effective at restoring dilator reactivity to
acetylcholine (Panel B).

The dilator response in UCMS-females in response to acetylcholine was reduced as

compared to that from controls, and pre-treatment with either L-NAME or indomethacin caused a further reduction in
reactivity (Panel C). Similar to that in UCMS-males, treatment of vessels from UCMS-females with TEMPOL
restored dilator responses to increasing concentrations of acetylcholine (Panel D).
The correlation between UCMS-induced changes in systemic inflammation and vascular dysfunction is
summarized in Figure 10 for TNF- (Panel A) and MCP-1 (Panel B). The degree of vascular dysfunction, estimated
from the lower bound of the methacholine concentration-response relationship for aortic rings (determined from the
logistic equation described above), demonstrated a positive relationship with the degree of systemic inflammation as a
result of the UCMS protocol. However, when split into sexes, a more severe relationship was evident in males, where
similar levels of either TNF- (Panel A) or MCP-1 (Panel B) was associated with a greater degree of vascular
dysfunction (i.e., a higher lower bound) in males than in females. This was evident under both control and UCMS
conditions. Interestingly, within either sex, imposition of the UCMS protocol did not appear to change the inherent
relationship between markers of inflammation and vascular dysfunction. Rather, the relationship between the
parameters remained similar, but was shifted to a higher severity of dysfunction.

DISCUSSION
With an escalating body of clinical and epidemiological evidence demonstrating that sex differences
influence the link between chronic stress, the onset of depressive symptoms and cardiovascular disease risk and
outcomes, validated preclinical models offer a valuable translational tool for investigating the underlying
mechanisms of disease and offer an efficacious method for studying novel interventional therapies and treatment
options. This study utilized the UCMS protocol, a validated model of chronic stress-induced depressive symptoms
in rodents, to interrogate sex-specific mechanisms of vascular dysfunction in UCMS mice.
The results of this study provide evidence that male and female mice experience graded outcomes related
to the severity of depressive symptom development and an almost paradoxically gradation of the impairment to
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vascular reactivity after 8 weeks of the UCMS protocol. Increased behavioral susceptibility to stress conditions
was observed in female mice versus male counterparts, as evidenced by worsened coat grooming score, increased
immobility in the tail suspension test (behavioral despair), and elevated plasma levels of corticosterone. Estrogen
levels are known to amplify the magnitude of the stress response at the HPA axis (4, 23, 57, 60, 61), offering a
potential explanation for the increased corticosterone and behavioral symptom severity observed in the UCMS
female mice.

UCMS-induced impairments to vascular reactivity and function were observed for both sexes,

demonstrated by blunting of dilator responses to methacholine/acetylcholine in isolated aortic rings and in
pressurized resistance arterioles, respectively. However, these physiological impairments were also sex-specific,
as female UCMS mice developed greater elevations to biomarkers of oxidative stress and inflammation, yet
demonstrated a more modest impairment to vascular reactivity, despite the more severe deterioration in the
behavioral measures.
Building on our previous report that vasodilator reactivity is blunted in aortic rings of UCMS male mice
(14, 26), our new findings suggest that the impaired dilator responses in UCMS mice of both sexes are due to
endothelial dysfunction, as dilations to exogenous NO were similar across all groups, as were constrictor
responses to phenylephrine, suggesting that an 8-week UCMS protocol is not sufficient to significantly alter
vascular wall mechanics or vascular smooth muscle function. Vasodilator responses were further blunted in
aortic rings and gracilis arterioles of UCMS females following pre-treatment with L-NAME; however this
treatment had minimal effects on vascular reactivity in UCMS males, likely owing to the pre-existing severe
attenuation of vascular NO bioavailability determined in UCMS males. Instead, the blunted dilator responses in
vessels from UCMS males were further impaired as a result of COX inhibition with INDO, suggesting that a
dependence on dilator influence of arachidonic acid metabolites (likely PGI2) helps to maintain vascular reactivity
in the compromised state. However, vascular PGI2 production alone did not correlate strongly across all of the
observed mechanical responses, suggesting a potential contributing role for other COX metabolites. Indeed, proinflammatory, oxidative stress conditions induced by chronic stress can alter the balance between constricting and
dilating metabolites, specifically shifting arachidonic acid metabolism by COX in favor of increased production
of vasoconstricting metabolites (e.g., thromboxane, TxA2) that can compete against the effect of stimulus induced
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vasodilation by NO, PGI2 or other dilator metabolites (14, 26). Our results suggest that an elevation in stimulusinduced vascular TxA2 generation may contribute to the integrated vasoreactivity in this model. Given the integral
role of inflammation and oxidant stress that has been demonstrated with chronic stress and depressive symptoms,
and the impact of chronic elevations in vascular TxA2 production will have on negative cardiovascular outcomes
in terms of perfusion control and the anti-thrombotic functions (among others) of the endothelium, the impact of
chronic inhibition of these pathways on both the behavioral and vascular outcomes in UCMS-induced depressive
symptoms clearly represents important areas for future interrogation.
While the results of this study found only very limited evidence of an increased vascular reactivity to
adrenergic constriction in UCMS males, these results largely appear to be a reflection of the degree to which
endothelial function was impaired as a result of the UCMS protocol. However, the vasoconstrictor response of
all animal groups to increasing concentrations of phenylephrine converged at a very similar levels following
inhibition of NOS activity via pre-treatment with L-NAME, suggesting that the role endogenous NO
bioavailability plays in moderating adrenergic constriction under normal conditions remains largely intact in
females despite UCMS, but is diminished in males following UCMS protocols.
The relationship between systemic inflammation induced by UCMS and the severity of vascular dysfunction
observed in males and females were investigated to determine sex differences in the effects of chronic
inflammation on vascular reactivity. Circulating plasma levels of pro-inflammatory markers MCP-1 and TNF-α
were associated with vascular dysfunction for all UCMS animals, but a greater degree of vascular dysfunction was
observed in UCMS-males than in UCMS-females, despite the observation that the magnitude of the inflammatory
markers was somewhat higher in female mice. When taken together with the higher plasma levels of ROS in
female UCMS mice versus males as well, these data suggest males experience a substantially greater endothelial
susceptibility to UCMS-induced dysfunction, raising the possibility of a protective mechanism for female sex
hormones that effectively reduces impairment of endothelium-dependent vasodilation during exposure to chronic
stress.
There is extensive evidence for the vasoprotective actions of estrogen against oxidative and inflammatory
stressors. Estrogen increases nitric oxide synthase activity and promotes NO bioavailability from the vascular
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endothelium (15, 27, 60); it is also linked to increased responsiveness to β2-adrenergic-mediated vasodilation (19,
21, 38), partially through a NO-related mechanism (19, 51). In addition to supportive effects on NO, estrogen
may also influence production of PGI2 via up-regulation of the COX pathway, specifically COX-1 and
prostacyclin synthase in some vascular beds (40, 51, 53, 60). While less is known regarding androgens, it has
been reported that testosterone supplementation impairs vascular reactivity and antioxidant capacity (10) in
females by mitigating vascular sensitivity to NO (11, 52). Females may therefore have a more robust and
protected endothelium-dependent vasodilator capacity than males due to higher levels of circulating estrogen and
significantly less testosterone, thus mitigating the inflammatory and oxidative effects of chronic stress on vascular
reactivity (13, 54, 60).
That being stated, the purpose of the study was not to test the effects of cyclic variation in estrogen levels on
vascular function, rather it was to determine the potential effect of a true difference in sex. As such, the female mice
used in this study were randomized within their estrous cycle. Given the robustness of the differences in outcomes
(both behavioral and vascular) as a result of the UCMS protocol, the fact that these mice were not studied at the same
points in their estrous cycle has significant implications. Most critically, these results suggest that the protective effect
associated with the female sex may not be critically dependent on the specific time within the estrous cycle or on
specific hormonal profiles at that time, but that it may be much more stable and afford a degree of protection that is
relatively insensitive to the day-to-day fluctuations in hormonal profiles. This is especially compelling as it suggests
that the potentially beneficial and protective mechanisms that are associated with the female sex remain in place
throughout the estrous cycle and may not fluctuate along the same temporal pattern as the hormonal levels. The
molecular basis for this temporal pattern, as well as the alternate hypothesis that the lower levels of androgen
hormones is actually the basis for the protection in this model of chronic stress and depressive symptoms and poor
cardiovascular outcomes, will require future targeted investigation.
Summary and Conclusions: In response to imposition of chronic unresolvable stresses onto male and female mice,
the results of the present study indicate that the behavioral impairments, elevations in plasma cortisol, and plasma
markers of oxidant stress and inflammation demonstrated by female mice are significantly greater than those
demonstrated by male mice. However, despite these elevated responses, the developed vasculopathy in both the
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conduit and resistance vasculature of female mice is less severe than that for males. Much of this blunted impairment
appears to be a function of a superior maintenance of endothelial function, primarily via more normal levels of NO
bioavailability and a more normal balance between the production of PGI2 and TxA2 to help maintain dilator
reactivity. As female rats were randomized with respect to their time in estrous cycle, these data appear to reflect a
longer, more temporally stable, protective effective of “being female” rather than one that reflects the more labile
temporal changes in hormonal levels. In addition, the correlational analyses between inflammatory biomarkers and
vascular dysfunction suggest that there are fundamental differences between male and female sex with regard to these
associations. However, imposition of the UCMS protocol does not appear to cause the differences in the sex-based
protections to diminish. Rather, UCMS appears to right-shift these associations along the same sex-specific lines to a
higher degree of vascular dysfunction.

Future research into the specific nature of the temporal nature of these

protective effects and how they can be exploited therapeutically to minimize the devastating effects of depressive
symptoms on cardiovascular health outcomes represents a key area for future investigation.
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Table 1. Baseline characteristics between mouse groups in the present study. All mice are aged 17-18 weeks.
* p<0.05 versus control.

Males

Females

UCMS-Males

UCMS-Females

(n=14)

(n=9)

(n=12)

(n=12)

Mass (g)

29±2

28±3

30±3

29±4

MAP (mmHg)

87±4

91±4

94±5

90±5

Insulinplasma (ng/ml)

1.1±0.3

1.2±0.4

4.1±0.7*

4.5±0.5*

Glucoseblood (mg/dl)

82±7

80±8

94±8

101±10

Cholesterolplasma (mg/dl)

71±7

68±8

78±6

77±10

Triglyceridesplasma (mg/dl)

94±6

101±8

109±8

116±12

Nitrotyrosineplasma (ng/ml)

12±3

11±4

29±5*

36±6*

Cortisolplasma (pg/ml)

12±3

14±4

29±5*

44±4*

TNF-plasma (pg/ml)

2.3±0.3

2.0±0.2

4.1±0.4*

6.4±0.4*†

MCP-1plasma (pg/ml)

2.8±0.3

3.3±0.5

10.2±1.0*

14.8±1.3*†
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FIGURE LEGENDS
Figure 1. Depressive symptoms following eight weeks of the UCMS protocol in male and female BALB/cJ mice.
Data are presented for coat status (Panel A), the latency (Panel B) and frequency (Panel C) of facial grooming
following a 10% sucrose solution spray, and the total period of immobility during the tail suspension test (Panel D)
for control and UCMS mice. Control males n=14; Control females n=9; UCMS males n=12, UCMS females n=12. *
p<0.05 versus Control in the sex; † p<0.05 versus UCMS-Male.

Figure 2. Constrictor responses of aortic rings to increasing concentrations of phenylephrine from mice under control
conditions and after eight weeks of UCMS. Data are presented under untreated conditions (Panel A) and in response
to NOS inhibition with L-NAME (Panel B). Control males n=12; Control females n=8; UCMS males n=10, UCMS
females n=10.

Figure 3. Dilator responses of aortic rings to increasing concentrations of methacholine from mice under control
conditions and after eight weeks of UCMS.

Panel A presents data under untreated conditions. Panels B and C

present data describing dilator responses from male and female Control mice, respectively, following pre-treatment
with L-NAME, indomethacin or combination. Panels D and E present data describing dilator responses from male
and female UCMS mice, respectively, following pre-treatment with L-NAME, indomethacin or combination. Control
males n=6-9; Control females n=5-7; UCMS males n=8-10, UCMS females n=7-10. * p<0.05 versus responses in
untreated vascular rings from control mice of that sex. † p<0.05 versus responses in untreated vascular rings from
UCMS-male mice.

Figure 4. Dilator responses of aortic rings to increasing concentrations of sodium nitroprusside from mice under
control conditions and after eight weeks of UCMS. Control males n=10; Control females n=8; UCMS males n=9,
UCMS females n=9.
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Figure 5.

Vascular production of nitric oxide (Panel A), PGI2 (Panel B; estimated from 6-keto-PGF1), and

TxA2 (Panel C; estimated from 11-dehydro-TxB2) following methacholine challenge in mice under control
conditions and following eight weeks of UCMS. Control males n=9; Control females n=7; UCMS males n=8,
UCMS females n=8. * p<0.05 versus responses in vessels from Control mice, † p<0.05 versus responses in
vessels from UCMS-Males.

Figure 6. Vascular production of nitric oxide following methacholine challenge in male and female mice
following eight weeks of UCMS. Data are presented for vessels under control (untreated) conditions, following
treatment of vessels from UCMS animals with TEMPOL and following treatment of vessels from UCMS animals
with L-NAME. Control males n=9; Control females n=7; UCMS males n=8, UCMS females n=8. * p<0.05 versus
responses in Control vessels from mice of that sex, † p<0.05 versus responses in untreated vessels of UCMS mice
of that sex, ‡ p<0.05 versus responses in UCMS+TEMPOL treated mice of that sex.

Figure 7. Dilator responses of aortic rings to increasing concentrations of methacholine from UCMS-Male (Panel A)
and UCMS-Female (Panel B) mice. Panel A presents data from UCMS-Males under untreated conditions, following
pre-treatment with TEMPOL, following treatment with TEMPOL/INDO, and following treatment with TEMPOL/LNAME. Panel B presents data from UCMS-Females under untreated conditions, following pre-treatment with
TEMPOL, following treatment with TEMPOL/INDO and following treatment with TEMPOL/L-NAME. Control
males n=8-11; Control females n=7-9; UCMS males n=8-9, UCMS females n=7-9. * p<0.05 versus responses in
untreated vessels, † p<0.05 versus responses in vessels that were pre-treated with TEMPOL.

Figure 8. Constrictor responses of gracilis arterioles to increasing concentrations of phenylephrine from mice under
control conditions and after eight weeks of UCMS. Data are presented under control conditions (Panel A) and in
response to NOS inhibition with L-NAME (Panel B). Control males n=10; Control females n=8; UCMS males n=10,
UCMS females n=10. * p<0.05 versus responses in arterioles from Control mice.
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Figure 9. Dilator responses of gracilis arterioles to increasing concentrations of acetylcholine from mice under
control conditions and after eight weeks of UCMS. Panel A presents data from male mice under untreated conditions
and following pre-treatment with L-NAME or indomethacin. Panel B presents data from male mice after pretreatment with TEMPOL alone or with L-NAME. Panel C presents data from female mice under untreated conditions
and following pre-treatment with L-NAME or indomethacin. Panel D presents data from female mice after pretreatment with TEMPOL alone or with L-NAME. Control males n=8-10; Control females n=7-8; UCMS males n=910, UCMS females n=8-10. * p<0.05 versus responses in vessels from Control mice of that sex; † p<0.05 versus
responses in vessels from UCMS mice of that sex.

Figure 10. Correlations between vascular reactivity and individual markers of chronic inflammation in control
male (blue), control female (red), UCMS male (green) and UCMS female (black) mice. Data are presented as the
lower bound of the methacholine concentration-response curve for an individual aortic ring versus plasma
concentrations of TNF- (Panel A) or MCP-1 (Panel B). In this figure, the lower bound from methacholine
concentration-response curve is reflective of the degree of dilator reactivity for that vessel. If the vessel is more
reactive to methacholine, the lower bound is decreased, while if the vessel becomes is less reactive, the lower
bound is increased. Also presented are lines of best fit through the data for each group, with the resulting slope
() and r2 values presented in the legend.
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CHAPTER 1: CONCEPTUAL FRAMEWORK
The conclusions from the study presented in this chapter demonstrated several novel findings and also
introduced three main questions, which are addressed in chapter 2 of this dissertation. The main findings can be
briefly summarized as follows:
- Unpredictable chronic mild stress- induced graded outcomes were associated with the severity of depressive
symptom development that differed between male and female BALBc/J mice. Specifically, female animals
exhibited a greater susceptibility to behavioral symptoms as measured by worsened coat score, increased
immobility in tail suspension, decreased sucrose-stimulated grooming, and elevated cortisol levels. In addition,
UCMS induced endothelial dysfunction in aortic rings and gracilis arterioles as evidenced by decreased
vasodilator response to agonist challenge, as well as reduced NO and PGI2 bioavailability, and increased TxA2
production. However, these impairments to vascular reactivity were more modest in UCMS females despite
worsened behavioral outcomes as well as greater levels of oxidative stress and inflammatory biomarkers
compared to UCMS males.
- Comparable levels of either TNF-α and MCP-1 was associated with a greater degree of vascular dysfunction in
males compared to females, and this relationship was observed in control as well as UCMS animals. In addition,
there was a shift of balance in COX metabolism, with a greater decrease in PGI2 and subsequent increase in TxA2
production observed in UCMS males.
- Using female mice that were randomized with respect to their time in estrous cycle allowed investigation of
potential interactions between the sex steroid hormones during the normal ovulatory cycle, when a milieu of sex
steroid hormones are present and fluctuating in a coordinated manner. This approach showed a longer, more
temporally stable protective effect of female characteristics rather than one that reflects the labile changes in
hormone status.
These observations led to the following questions, which form the basis of the next chapter of this
dissertation. Chapter 2 will focus on a enhancing the translational relevance of the study as further investigations
of potential sex-specific mechanisms linking chronic stress, depressive symptoms, and peripheral vascular
dysfunction continue.
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1. To increase the translational value of the experimental model, rats will be used for the remainder of the
projects. The mechanisms and pathology of disease in rats is more comparable to that of humans. Will the
sex specific functional outcomes utilizing the same relevant model of stress-induced depression reflect
similar findings using a new species model?
2. Given the sex disparities to UCMS seen in mice regarding protection of vascular function, what roles do
female sex hormones play in conferring protection against endothelial dysfunction?
3. Given the prevalence and increased risk of depression in individuals with CVD, what impact would
UCMS have on behavioral outcomes and vascular function in an animal model with pre-existing CVD
risk factors?
The next chapter of this dissertation sought to answer these three questions in the Obese Zucker rat (OZR), a
model of metabolic syndrome. The OZR, with its inherent development of obesity, insulin resistance, moderate
hypertension, and hyperlipidemia represents an excellent model of CVD risk, and while there have been
numerous studies describing alterations to vascular reactivity and microvascular network structure/mechanics in
OZR, there is limited data addressing the impact of chronic stress/depressive symptoms in an integrated system of
pre-existing poor CVD health. Thus, both male and female OZR, along with their lean controls, were used to
investigate the effects of comorbid metabolic syndrome and UCMS on behavioral and vascular outcomes. A
separate cohort of ovariectomized female LZR and OZR was included to specifically investigate the impact of
estrogen deficiency on physiologic stress response in female animals.
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ABSTRACT
The prevalence and severity of depression is tightly linked to development of cardiovascular disease
(CVD) and cardiovascular events; the steadily rising incidence of comorbid pathology exacerbates negative
cardiovascular outcome and greatly impacts the efficacy of clinical treatments/interventions. Furthermore, the
marked sex disparity in incidence, clinical presentation, and health outcomes of depression and CVD presents an
additional significant hurdle for public health practices. The unpredictable chronic mild stress (UCMS) protocol is
a translationally relevant model for imposing depressive symptoms in rodents, resulting in sex specific behavioral
and physiological outcomes. Sex specific effects have been attributed to female hormones, specifically, a
cardioprotective effect of estrogen that mitigate UCMS induced vasculopathy. Therefore, the effects of UCMS in
females lacking ovarian hormone production (OVX) were assessed in both healthy rats and in genetically
modified rats that are pre-disposed to metabolic syndrome. The results suggest that sex hormones are
differentially regulated in female rats as a result of pre-existing CVD risk factors that alter lipid profiles and
inflammatory conditions that exacerbate negative health outcomes. Additionally, comorbid depression and CVD
altered the behavioral outcomes in male and female animals compared to healthy controls.

Key Words: vasodilation, endothelial dysfunction, chronic stress, clinical depression, sex disparities, metabolic
syndrome, cardiovascular risk factors
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INTRODUCTION
Cardiovascular disease is the leading cause of death for both men and women in the United States (Center
for Disease Control). Over the past decade, an extensive body of clinical evidence has identified depression as a
predictor of CVD risk factors that are independent of other traditional cardiovascular risk factors in patients with
or without overt CVD (Patel et al., 2008; Plante et al., 2005; Whiteford et al., 2013).

Substantial

evidence

indicates that chronic stress, a major contributing factor in depression onset, is a significant driving factor in the
development of CVD and associated antecedent risk factors (Bayramgurler et al., 2013; Barden et al., 2004; Beck
et al., 2002) while also demonstrating more predictive of CVD than traditional CV risk factors. (Everson-Rose et
al., 2005). Chronic stress- induced dysfunction of the physiologic stress response systems, the sympatheticadrenal-medullary (SAM) and hypothalamic-pituitary-adrenal (HPA) axes, causes sex-specific pathophysiological
events strongly linked to both depression and the development of CVD, including autonomic nervous system and
immune dysfunction, as well as impairments to vascular reactivity and endothelial function.
The CDC and National Association of Mental Illness report that adult women are twice as likely to suffer
from depression compared to men (Kuehner et al., 2003), with risk fluctuating in correspondence with hormone
status (Steiner et al., 2003). However, premenopausal women have lower rates of major CV events compared to
same-aged men, despite the presence of comparable CVD risk factors. Beginning at menopause, corresponding
with reduced ovarian hormone production, CVD incidence rapidly rises; correspondingly, the presence of
underlying risk factors including diabetes mellitus, hypertension, smoking, hypercholesterolemia, and obesity
heighten risk of major CV events compared to same-aged men (Vaccarino et al., 1999; Bello and Mosca, 2004;
Kenachaiah et al., 2004; Mähönen et al., 2004; Polk and Naqvi, 2005). The loss of sex-specific protective effects at
menopause has largely been attributed to a substantial decline in ovarian production of hormones, specifically
estrogen, which has major roles in conferring CV protection as well as antioxidant effects. Studies in chronically
stressed female rodents have demonstrated a protective effect against stress-induced vasculopathy through
preservation of endothelial function in both large and small arteries versus male counterparts (Stanley et al., 2014).
However, the specific mechanisms governing the complex relationship between sex-specific vascular pathologies,
chronic stress/depression, and general CVD risk factors are not well established.
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The unpredictable chronic mild stress (UCMS) procedure has been validated in behavioral studies as a
highly relevant rodent model of clinical depression based upon its ability to reproduce symptoms of depression,
including anhedonia and learned helplessness (Willner, 1997; Grippo, 2005). Importantly, the UCMS protocol is
also ideally suited to study the vascular effects of chronic stress and depression. Animals subjected to UCMS
exhibit impaired endothelial-dependent vasodilation associated with decreased nitric oxide (NO) bioavailability
and increased pro-inflammatory, pro-oxidative conditions (d’Audiffret et al., 2010), similar to clinical signs of
CVD (Isingrini et al., 2012; Willner et al., 1997). Studies utilizing the UCMS protocol have shown that female
rodents have a greater susceptibility to depressive-like behaviors (Krishnan et al., 2010; Plante et al., 2005), but a
less severe impairment of vascular endothelial function compared to male animals (Stanley et al., 2014). These
positive, protective effects on vascular function in female animals during chronic stress conditions have been
linked to specific estrogen actions (Dalla et al., 2005; Grippo et al., 2005; Wang et al., 2014) in promoting
antioxidant defense and NO bioavailability that are necessary for normal endothelial function and vascular antiinflammatory and antioxidant capacities (Rupnow et al., 2001).
This purpose of this study is to further elucidate the role of female sex hormone (estrogen) in modulating the
physiological response to chronic mild stressors, the development of depressive symptoms, and the corresponding
development of stress-induced vascular dysfunction in female rodents with deficient estrogen levels as a result of
ovariectomy (OVX). Furthermore, most studies to date have focused on the effects of chronic stress/depression in
healthy animals, while investigation of these effects in models of comorbid cardiovascular risk factors are largely
lacking. As such, this study will interrogate this complex bidirectional relationship between depression and CVD
using an animal model exhibiting a complex state of poor cardiovascular health similar to that of human disease. To
this end, the obese Zucker rat (OZR; Leprfa/fa) is a valid representative model of the cardiovascular risk factors that
comprise the metabolic syndrome. Due to a mutation of the leptin receptor, the OZR develops chronic
hyperphagia that progressively leads to development of moderate hypertension, hypercholesterolemia,
hypertriglyceridemia, hyperglycemia, and insulin resistance, which are characterized in metabolic syndrome in
human subjects.
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Eight weeks of UCMS were imposed on male, female, and ovariectomized female lean and obese Zucker rats
(LZR, OZR) at 9 weeks of age to determine first, the effects of co-morbid chronic stress and CV risk on the
development of depressive symptoms and vascular dysfunction in a model of the metabolic syndrome; and secondly,
to investigate the impact of estrogen deficiency on vascular outcomes of chronic stress in both healthy females and
females with comorbid metabolic syndrome.

MATERIALS AND METHODS
Animals: Male and female LZR and OZR (Harlan) were fed standard chow and drinking water ad libitum and were
housed in the animal care facility at the WVU HSC. A separate cohort of ovariectomized (OVX) female LZR and
OZR (Harlan) were similarly housed; OVX was performed by Harlan Laboratories prior to animal shipment. All
protocols received prior IACUC approval. At nine weeks of age, rats from each sex were divided into two groups,
control and UCMS (below). After eight weeks duration under either control or UCMS conditions, rats were
anesthetized with injections of sodium pentobarbital (50 mgkg-1 i.p.) and a carotid artery was cannulated for
determination of mean arterial pressure. Venous blood aliquots were collected by venipuncture for biochemical
evaluation of plasma biomarkers of treatment outcomes and metabolic health status of the rats.
Unpredictable Chronic Mild Stress Protocol: All rats were singly housed, with the control group in a separate quiet
room in close proximity to the room used for UCMS treatments. Alternatively, in the UCMS group, rats were
randomly exposed to the following mild environmental stressors on multiple occasions throughout each 24 hour
period water temperature was ~30°C and the room temperature was ~24°C:
1. Damp bedding – 10 oz. of water was added to each standard cage for the next 3 hours
2. Water – all bedding was removed and ~0.5 inches of water was added to empty cage for the next 3 hours.
3. Each cage was tilted to 45 degrees with or without bedding for 3 hours
4. Social stress – each rat was switched into a cage of a neighboring rat for 3 hours
5. No bedding lasting for 3 hours or, on two occasions each week, overnight.
6. Succession of light/dark cycles, lasting 30 minutes throughout a 24 hour period
7. Exposure to predator smells (e.g., cat fur) and/or sounds (e.g., cat growling) for 8 hours
68

8. After eight weeks, all rats were subjected to a series of behavioral tests to evaluate the outcomes of the
UCMS procedures.
Coat Status: This evaluation was done throughout the duration of the UCMS protocol. The total cumulative score
was computed by giving an individual score of 0 (clean) or 1 (dirty) to eight body parts (head, neck, dorsal coat,
ventral coat, tail, forelimb, hind-limb, and genital region).
Splash Test: This test was used to evaluate acute grooming behavior, defined as cleaning of the fur by licking or
scratching. A 10% sucrose solution was sprayed on the dorsal coat of each rat and grooming activity was recorded for
five minutes. The viscosity of the sucrose solution will dirty the coat and induce grooming behavior, with depressive
symptoms characterized by an increased latency (idle time between spray and initiation of grooming) and
decreased frequency (number of times grooming a particular body part).
Measurements of Vascular Reactivity (Conduit Arteries): Following removal of the resistance arteriole in each rat,
the thoracic aorta was removed, rinsed in physiological salt solution, cleared of surrounding tissue, and cut in 2-3 mm
ring segments. Each ring was mounted in a myobath chamber between a fixed point and a force transducer (World
Precision Instruments), and set to 0.5 g tension for 45 minutes to equilibrate. The organ baths contained physiological
salt solution at 37ºC, and aerated with 95% O2 and 5% CO2. Rings were pre-conditioned by treatment with 10-7 M
phenylephrine for 5 minutes, at which time 10-5 M methacholine was added to the bath to assess endothelial integrity.
Any ring that failed to demonstrate both a brisk constrictor response to phenylephrine and viable endothelial function
was discarded. Subsequently, rings were treated with increasing concentrations of phenylephrine (10-10 M – 10-4 M)
to assess constrictor reactivity.

For the assessment of dilator reactivity, rings were pre-treated with 10-6 M

phenylephrine and exposed to increasing concentrations of methacholine (10-10 M – 10-4 M) and sodium nitroprusside
(10-10 M – 10-4 M). To assess the roles of nitric oxide, cyclooxygenase and reactive oxidant stress in modulating
vascular responses to the agonist treatments, concentration-response curves were also conducted following pretreatment of the rings for 45-60 minutes with L-NAME (10-4 M), indomethacin (10-5 M), and TEMPOL (10-4 M),
respectively.
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Biochemical Analyses: Plasma corticosterone was determined using standard EIA kits (Cayman Chemical). Plasma
insulin and biomarkers of inflammation were measured by a multiplexed electrochemiluminescence platform (Meso
Scale Diagnostics).
Data and Statistical Analyses: Mechanical responses following challenge with methacholine or phenylephrine were
fit with the three-parameter logistic equation:

 max  min 
y  min  
log ED x
1  10 50 
where y represents the isometric tension, “min” and “max” represent the lower (minimum) and upper (maximum)
bounds, respectively, of the change in tone with agonist concentration, x is the logarithm of the agonist concentration
and log ED50 represents the logarithm of the agonist concentration ( x ) where the response ( y ) is halfway between
the bounds.

The use of the three-parameter logistic equation is appropriate for the analysis of sigmoidal

concentration-response relationships, as it simultaneously provides estimates of the curve maximum (upper bound),
minimum (lower bound) and the dose at which the dependent variable reaches 50% of maximum (ED50). In the case
of a dilator response where the initial condition is set to 100% (the upper bound), the asymptotic minimum (the
lower bound from the equation) is reflective of the degree of dilator reactivity for that vessel. If the vessel
becomes “more reactive”, the lower bound will decrease toward reduced levels, while if the vessel becomes less
reactive, the lower bound will increase toward higher values. This situation is reversed for constrictor responses,
where the vessel starts at the lower bound, and then goes through a range of increased tensions to reach an upper
bound/asymptotic maximum.

For the presentation of results, we have focused on the changes in the upper or

lower bounds, as we did not determine a consistent or significant change to the ED50 values between relevant
experiment groups.
All data are presented as mean±SEM. Significant differences between groups were determined using
analysis of variance (ANOVA). In all cases, Student-Newman-Keuls post hoc test was used when appropriate and
p<0.05 was taken to reflect statistical significance.
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RESULTS
Table 1 presents data describing the characteristics of LZR and OZR under control and UCMS conditions.
After 8 weeks of UCMS, plasma glucose was significantly greater in male and female LZR versus same sex
controls, while only elevated in UCMS female OZR versus control female OZR. Inflammatory biomarkers
(TNFα, IL-6, IL-1β) were increased in UCMS animals (versus respective controls), and both female-UCMS LZR
and OZR exhibited higher levels of all three inflammatory cytokines versus male-UCMS LZR and OZR,
respectively. Plasma levels of corticosterone were significantly increased with UCMS in both sexes (OZR and
LZR) as compared to relative controls (p<0.05); corticosterone levels were significantly greater in UCMS-female
LZR than that in UCMS-male LZR (p<0.05).
The impact of the UCMS protocol on depressive behaviors in lean and obese rats is summarized in Figure
1. Throughout 8 weeks of UCMS, the coat status in LZR (Panel A) and OZR (Panel B), undergoing the stress
protocol were consistently poorer compared to that in respective control animals (p<0.05), and the severity of this
degradation in coat status was significantly worse in UCMS-female LZR (p<0.05) versus UCMS male LZR,
while no differences were observed between the sexes in OZR.
In response to the sucrose spray, UCMS animals, both LZR and OZR, demonstrated both a less rapid
(Panel C) and less frequent (Panel D) grooming response as compared to that exhibited in respective
controls(p<0.05). Significant differences (p<0.05) between the sexes were observed only in LZR (greater latency
and reduced grooming in females) but not OZR following UCMS.
The constrictor responses of aortic rings from lean and obese rats in response to increasing concentrations
of phenylephrine are summarized in Figure 2. As compared to responses in aortic rings from control male LZR,
rings from UCMS-LZR males exhibited a similar constrictor response to the adrenergic agonist (Panel A). In
female LZR, the constrictor response of aortic rings was not significantly different between control and UCMS;
however, compared to all groups, constrictor reactivity was least in control females. In OZR, PE-induced
constrictor responses were elevated in UCMS animals compared to controls, and this was more pronounced in
female OZR (p<0.05).
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The methacholine-induced dilator responses of aortic rings from control and UCMS-LZR are presented in
Figure 3. In comparison to responses from control LZR, the dilation to increasing concentrations of methacholine
was significantly reduced in both male and female UCMS LZR, although the severity of this blunted response in
aortic rings from UCMS-males (Panel A) was greater (p<0.05).
Figure 4 presents vasodilator responses in aortic rings of LZR following pre-treatment with various
inhibitors. In vessels of control male and female LZR (Panels A and B), pre-treatment with L-NAME resulted in a
significant inhibition of methacholine-induced dilator reactivity while pre-treatment with indomethacin showed a
less striking, although still significant, attenuation in dilation (p<0.05). In aortic rings from UCMS-male LZR
(Panel C), pre-treatment with L-NAME had minimal effects on further blunting dilator responses while
indomethacin almost diminished dilator response to methacholine (p<0.05). In conduit artery segments from
UCMS-female LZR, treatment with L-NAME significantly reduced methacholine-induced dilation (p<0.05),
while responses following treatment with indomethacin was less blunted (Panel D). In all cases, combined
treatment with both L-NAME and indomethacin nearly abolished the reactivity of aortic rings to increasing
concentrations of methacholine.
The methacholine-induced dilator responses of aortic rings from control and UCMS-OZR are presented in
Figure 5. In comparison to responses from control OZR, the dilation to increasing concentrations of methacholine
was significantly reduced in both male and female UCMS OZR (p<0.05), but differences between sexes was not
observed. In UCMS male OZR (Panel B) and UCMS female OZR (Panel C) aortic dilator responses were
severely attenuated, potentially with a near complete loss of both NO and PGI2 bioavailability.
Figure 6 summarizes the responses of aortic rings from control and UCMS rats to increasing
concentrations of sodium nitroprusside. In both LZR (Panel A) and OZR (Panel B), application of the nitric oxide
donor resulted in similar dilator responses between control and UCMS rats of both sexes.
Table 2 presents data comparing the characteristics of control and UCMS OVX LZR and OVX OZR
versus their respective intact female animals. OVX was associated with increased weight in both LZR and OZR
versus respective intact females (p<0.05). Plasma glucose and inflammatory biomarkers (TNFα, IL-6, IL-1β)
were increased in OVX LZR versus intact females, both with control and UCMS (p<0.05), and these were
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elevated in UCMS OVX LZR versus control OVX LZR. While plasma glucose and inflammatory biomarkers
were significantly elevated in control OVX OZR versus intact control OZR (p<0.05), UCMS did not have an
additive effect on increasing these markers in OVX OZR compared to intact UCMS OZR. Triglyceride,
cholesterol, LDL, and non LDL were all significantly greater in OVX OZR compared to OVX LZR (data not
shown).
Figure 7 shows the impact of the UCMS protocol on depressive behaviors in lean and obese OVX rats
versus intact lean and obese females, respectively. In control conditions, coat status in OVX LZR (Panel A) and
OVX OZR (Panel B) was not different from respective intact control females. With UCMS, OVX LZR exhibited
an attenuated deterioration of coat status compared to intact UCMS LZR (p<0.05), and while this pattern was
trending in the OZR, the lowered coat score in UCMS OVX OZR (compared to intact UCMS OZR) did not reach
significance until the last week of UCMS (p<0.05).
Loss of estrogen had a substantial effect on vasodilator responses in aortic rings of LZR females,
summarized in Figure 8. In control LZR, OVX blunted vasodilator response to methacholine, resulting in a
similar degree of vascular dysfunction observed in intact female LZR subjected to UCMS (p<0.05), shown in
Panel A. The effects of chronic stress further exacerbated impaired vascular reactivity in OVX LZR (p<0.05).
When compared to UCMS males, vasodilator response of UCMS OVX females converged at a very similar level,
suggesting that lack of estrogen has a role in attenuating sex specific effects of UCMS on vascular function (Panel
B). Following pre-treatment with L-NAME, vasodilator responses to methacholine were abolished in both control
OVX LZR (Panel C) and UCMS (Panel D). In contrast, indomethacin had less substantial effects on vasodilation
in OVX control, while indomethacin (at the highest treatment concentration) minimally improved the blunted
response in OVX UCMS LZR compared to non-treated conditions.
Figure 9 presents the dilator responses of aortic rings from control and UCMS OVX OZR in response to
increasing concentrations of methacholine. OVX had minimal effects on dilator responses to methacholine in
either control or UCMS conditions compared to control and UCMS intact OZR, respectively (Panel A).
Treatment with L-NAME completely knocked out dilation in both control (Panel B) and UCMS (Panel C) OVX
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OZR. Inhibition of COX with indomethacin had no effect on vasodilator response in control OVX OZR, while
minimal improvement of blunted response (vs. untreated conditions) occurred in OVX UCMS OZR.
Pre-treatment of conduit vessels from UCMS OVX females with TEMPOL (Figure 10) restored
vasodilator responses in UCMS OVX LZR to a similar level of untreated OVX control LZR (Panel A). A similar
trend was observed in OVX OZR (Panel B), showing TEMPOL improved dilation in UCMS OVX OZR to that of
OVX OZR under control conditions. TEMPOL had minimal effects on vasodilator responses of both control
OVX LZR and OZR (data not shown).

DISCUSSION
With a growing body of evidence from clinical and epidemiological studies in support of a substantial sex
disparity associated with both the incidence and severity of depression and the development of CVD risk factors,
translationally relevant animal models can be used to facilitate further investigations into functional outcomes,
underlying mechanisms, and novel therapeutic strategies.
In previous studies, we observed that 8 weeks of UCMS in BALBc/J mice induced behavioral changes that
are characteristic of clinical depression (progressive failure to groom; lack of self-stimulatory behavior; and an
elevation of circulating cortisol levels) (d’Audiffret et al., 2011; Stanley et al., 2014). In addition, UCMS also
significantly impacted vascular reactivity and endothelial function in the gracilis arteriole and aortic rings, as
evidenced by alterations to dilator/constrictor balance and impaired endothelial dependent vasodilator response to
agonist challenge, as well as promotion of pro inflammatory, pro oxidative conditions within the vasculature.
Furthermore, in female mice (versus males), more severe depressive symptoms and greater elevations in plasma
cortisol were observed, although the degree of vascular dysfunction was attenuated compared to males; this was
suggested to be due to the ability to attenuate the effects of elevated ROS and inflammation on dilator responses.
The data suggest that female mice are more susceptible to chronic stress- induced depressive behaviors but have a
greater ability to tolerate elevated ROS and systemic inflammatory stress that blunted the subsequent
development of vasculopathy compared to males. The purpose of this study was to interrogate the behavioral and
physiological effects of chronic exposure to exogenous stressors in male and female rats, under conditions of health as
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well as with pre-existing metabolic syndrome. In addition, these parameters were also measured in ovariectomized
(OVX) females in order to interrogate the effects of ovarian hormone deficiency.
Similar to previous reports, female LZR developed more severe depressive like behaviors with UCMS, as
evidenced by a deterioration of the coat score and decreased grooming behavior, as well as elevated circulating
corticosterone levels, compared to male LZR. Interestingly, although no significant difference between sexes occurred
in the OZR, development of depressive like behaviors was not only observed with UCMS, but also in non-stressed
animals. This suggests that OZR develop depressive phenotypes in the absence of environmental stress challenges.
Unpublished data from our laboratory demonstrate progressive worsening of depressive-like behaviors with age (10 to
19 weeks) as evidenced by deterioration of coat status and elevation of plasma cortisol in OZR males in the absence
of additional intervention, and this has been supported in behavioral studies using the OZR (Li et al., 2014).
Furthermore, similar models of metabolic syndrome with various genetic mutations of the leptin-receptor demonstrate
a pre-disposition towards depressive behaviors (Sharma et al., 2010; Yamada et al., 2011, Guo et al., 2013),
indicating a potential role of leptin signaling in the development of depression.
UCMS-induced impairments to vascular vasodilator responses in female LZR were less severe compared
to that of males (24% reduction in vasodilation vs. 40%), supporting numerous other reports of superior vascular
function in females subjected to stress regimens. In addition, vasodilator responses were further blunted in aortic
rings of UCMS female LZR following pre-treatment with L-NAME, while this had minimal effects in UCMS
males. Instead, UCMS male LZR showed greater dependence on COX metabolites, like PGI2, likely to maintain
dilator responses during compromised NO bioavailability. In contrast to the disparate results observed between
male and female LZR, there was no significant difference in vascular reactivity between male and female OZR (50%
reduction in response versus OZR control), indicating a loss of sex-specific vascular protection to UCMS that is
associated with significant reductions of both P PGI2 and NO bioavailability. While confirming vascular protection to
stress in the female LZR, the similarity of impairment between the sexes in the UCMS OZR may be a result of
significant loss of sex-specific vasoprotective vascular mechanisms in chronically stressed females with preexisting CVD risk.
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Heightened sensitivity to adrenergic challenge was observed in UCMS male and female OZR via
increased contractility of aortic rings to the α-adrenergic receptor agonist phenylephrine.

Increased sympathetic

activity has been etiologically linked not only with depression, but also with the development of some components of
metabolic syndrome such as dyslipidemia and hypertension, as well as vascular risk factors including platelet
activation and increased pro-inflammatory factors (Goldstein et al., 1983; Golden et al., 1988; Anfossi et al., 1996).
Persistent sympathetic over-activity associated with chronic stress/depression and metabolic syndrome may
exacerbate vascular dysfunction, as studies in our lab have demonstrated enhanced α-adrenergic vasoconstriction in
arterioles of OZR, resulting in impaired blood flow to skeletal muscle and the microvessel networks that negatively
affect tissue perfusion (Frisbee, 2002).
It is increasingly evident that chronic activation of pro-inflammatory pathways may be partly responsible for
obesity-induced metabolic disorders (Wellen et al., 2005). Biomarkers of inflammation (TNF-α, IL-6, IL-1β) were
greater in UCMS animals relative to their respective controls, with greatest elevation in obese animals. Comorbid
metabolic syndrome and depression seemed to mitigate the protective vascular mechanisms to UCMS observed in
lean females; this may be partially attributed to the severity of the chronic inflammatory microenvironment in UCMS
female OZR. Advanced metabolic disease coupled with chronic stress may simply overwhelm the stress response at
the most basic mechanistic levels, resulting in chronic, systemic inflammation and unmitigated oxidative stress
associated with the severe endothelial dysfunction demonstrated in UCMS OZR in this study.
OVX and UCMS
The effects of female sex hormone deficiency on behavioral outcomes and vascular dysfunction induced
by UCMS were investigated in lean and obese animals. Estrogen in particular has been implicated in a range of
antioxidant vasculoprotective functions; OVX was therefore performed on female animals to eliminate the major
source of estrogen production. Following UCMS, both OVX OZR and LZR developed depressive symptoms (i.e.
worsened coat score and decreased grooming), though these impaired behaviors were less severe than intact
UCMS female OZR and LZR, respectively, with no change in control conditions. Loss of estrogen may impact
the severity of developed behavioral responses under conditions of induced chronic stress that are attenuated or
less striking in non-stressed conditions. As women are twice as likely to develop depression, specifically during
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times of intense hormone fluctuations (Steiner et al., 2003), it may be that lack of constant estrogen cycling in
OVX animals confers a long term effect on behavior that attenuates depressive symptoms. However, behavioral
effects mediated by estrogen have demonstrated controversial findings in both animal and human studies.
Local vascular factors, such as NO, are important regulators of peripheral resistance and endothelium and
VSM function. NO bioavailability is essential for regulation of blood pressure and local blood flow, in addition to
its inhibitory actions on platelet aggregation, thrombus formation, and leukocyte adhesion. Increasing evidence
suggests that the vasculoprotective effects of estrogen are due to enhancement of vascular NO bioavailability as
well as its functional role in antioxidant defense and anti-inflammatory mechanisms in multiple different tissues
(Thompson et al., 2000). In this study, L-NAME completely abrogated vascular reactivity in all OVX animals,
indicating severely compromised NO bioavailability in estrogen deficient animals. In addition, estrogen may also
influence production of PGI2 via up-regulation of the COX pathway, specifically COX-1 and prostacyclin
synthase (Sherman et al., 2002), implicating a role of estrogen in regulating vasodilator and vasoconstrictor
balance of arachidonic acid metabolites. For example, conditions of estrogen deficiency in women (i.e., aging,
hypertension, and diabetes) are associated with a shift in favor of COX-dependent vasoconstrictors over
vasodilators. Alterations in COX metabolism have been associated with differential effects on methacholinestimulated endothelium-dependent dilation between males and females (Li et al., 2008), specifically during conditions
of chronic stress/depression (Stanley et al., 2014). In contrast to intact lean and obese females, minimal effects were
observed following inhibition of COX with indomethacin in OVX animals, indicating lack of PGI2 in vasodilator
responses to methacholine and/or altered vasoconstrictor mediated activity in OVX state. Together, alterations in NO
and TxA2 bioavailability in the vascular network of OZR have been demonstrated to contribute to significant changes
in the severity of adrenergic constriction, myogenic activation, and the integration of these components on regulating
vascular tone (Frisbee et al., 2002), which is potentiated under comorbid depression.
Loss of estrogen alone was sufficient to attenuate vasodilator response to methacholine challenge in
control females, suggesting that OVX blunts vascular reactivity under non-stressed conditions. Following UCMS,
OVX further blunted vasodilator responses in LZR, so that the level of vascular dysfunction was comparable to
that of UCMS male LZR. It appears that loss of estrogen in lean females is associated with failure to confer
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protection against chronic stress- induced vasculopathy, resulting in similar vascular outcomes to males. A similar
relationship in vascular dysfunction between intact lean and obese females mentioned previously was sustained in
OVX conditions, but just shifted to a higher degree of dysfunction with estrogen loss. Furthermore, increased
inflammatory markers (TNF-α, IL-6, IL-1β) in OVX females may be due to loss of estrogenic anti-inflammatory
action, which was exacerbated with UCMS. Hyperglycemia and increased body mass may have additional effects in
promoting oxidative conditions (Perez-Torres, et al., 2008), further impairing NO bioavailability and promoting
inflammation. Comorbid depressive symptoms and metabolic syndrome induce an inflammatory environment that
overwhelms compensatory mechanisms and results in severe vascular impairments, adverse outcomes that are
exacerbated by removal of estrogen by OVX in this study.
The effects of OVX and chronic stress appear to impact vascular reactivity differently in lean versus
obese females. For example, in LZR, the severity of impaired vasodilator responses was more associated with
OVX, while OVX appeared to have less of an impact on vascular reactivity in OZR compared to that of chronic
stress (with UCMS). This was in parallel to inflammatory biomarker levels, which were substantially greater in
OVX LZR versus intact LZR, while comparable between OVX OZR and UCMS OZR. While beyond the scope
of this study, female OZR have been reported to be infertile as a result of reduced levels of sex hormones, and
such attenuated activity may in part explain the smaller impact of OVX on vascular function in OZR. It is
possible that restoring functional activity of ovarian hormones with exogenous administration of estrogen may
have a more pronounced effect on vascular function in female OZR. In addition, estrogen has a major role in body
weight homeostasis, lipid metabolism, glycemic control, and total and central abdominal adiposity and this has
been associated with variable effects in high-risk CVD individuals (Mallei et al., 2006; Perez-Torres et al., 2008).
Results presented here show that OVX OZR had significantly increased levels of triglycerides, cholesterol, and
low density lipoprotein levels compared to OVX LZR, which could be major sources of oxidative stress and
inflammation in this CV model. However, another study using the OZR demonstrated unfavorable effects of
estrogen on triglyceride and cholesterol profiles that exacerbated metabolic abnormalities associated with
underlying metabolic syndrome (Gades et al., 1998). Taken together, it is possible that the beneficial effects of
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estrogen on vascular health are overwhelmed by the pro-inflammatory, oxidative environment in OZR, thereby
contributing to similar outcomes in OVX and intact OZR females.
These results support the role of inflammation, oxidative stress, and decreased NO bioavailability as
important mechanisms contributing to chronic stress-induced vascular dysfunction in estrogen-deficient lean and
obese females. Understanding the variables associated with the relationship between obesity and depression is
essential given the increased health risks associated with comorbidity and the potential implications for sex
specific prevention and treatment plans of comorbid obesity and depression.
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FIGURE LEGENDS
Figure 1. Depressive symptoms following eight weeks of the UCMS protocol in male and female LZR and OZR.
Data are presented for LZR coat status (Panel A), OZR coat status (Panel B), the latency (Panel C) and frequency
(Panel D) of facial grooming following a 10% sucrose solution spray in LZR and OZR. Control male LZR, OZR
n=8; Control female LZR, OZR n=8; UCMS male LZR, OZR n=8, UCMS female LZR, OZR n=8.

*p<0.05

versus controls in the same sex group (LZR or OZR); † p<0.05 versus UCMS-males of the same group (LZR or
OZR).
Figure 2. Constrictor responses of aortic rings to increasing concentrations of phenylephrine from rats under
control conditions and after eight weeks of UCMS. Data are presented for LZR (Panel A) and OZR (Panel B).
Control male LZR, OZR n=8; Control female LZR, OZR n=8; UCMS male LZR, OZR n=8, UCMS female LZR,
OZR n=8. *p<0.05 versus controls in the same sex group (LZR or OZR).
Figure 3. Dilator responses of aortic rings to increasing concentrations of methacholine from LZR under control
conditions and after eight weeks of UCMS. Panel A presents data under untreated conditions. Control male LZR
n=8; Control female LZR n=8; UCMS male LZR n=8, UCMS female LZR n=8. *p<0.05 versus dilator responses
in same sex control; † p<0.05 versus UCMS-male LZR.
Figure 4. Dilator responses of aortic rings to increasing concentrations of methacholine from LZR under control
conditions and after eight weeks of UCMS.

Dilator responses from control male (Panel A) and control female

(Panel B)control LZR are shown following pre-treatment with L-NAME, indomethacin or combination. Panels C
and D present data describing dilator responses from male and female UCMS LZR, respectively, following pretreatment with L-NAME, indomethacin or combination. Control male LZR n=8; Control female LZR n=8;
UCMS male LZR n=8, UCMS female LZR n=8. *p<0.05 versus untreated aortic rings; † p<0.05 versus UCMSmale LZR.
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Figure 5. Dilator responses of aortic rings to increasing concentrations of methacholine from OZR under control
conditions and after eight weeks of UCMS.

Panel A presents data from untreated vessels in male and female

OZR. Panel B presents data describing dilator responses from male UCMS OZR, following pre-treatment with LNAME, indomethacin or combination. Panel C presents data describing dilator responses from female UCMS
OZR, following pre-treatment with L-NAME, indomethacin or combination. Control male OZR n=8; Control
female OZR n=8; UCMS male OZR n=8, UCMS female OZR n=8. *p<0.05 versus responses in control/untreated
conditions.
Figure 6. Dilator responses of aortic rings to increasing concentrations of sodium nitroprusside from rats under
control conditions and after eight weeks of UCMS. Panel A presents data from LZR. Panel B presents data from
OZR. Control male LZR, OZR n=8; Control female LZR, OZR n=8; UCMS male LZR, OZR n=8, UCMS female
LZR, OZR n=8.
Figure 7. Depressive symptoms following eight weeks of the UCMS protocol (versus respective control) in OVX
LZR (versus intact female LZR) and OVX OZR (versus intact female OZR). Data are presented for LZR coat
status (Panel A) and OZR coat status (Panel B), in both OVX and intact females. Control female LZR n=8;
Control OVX LZR n=8; UCMS female LZR n=8, UCMS OVX LZR n=8, Control female OZR n=8; Control
OVX OZR n=8; UCMS female OZR n=8, UCMS OVX OZR n=8. *p<0.05 versus intact control females; †
p<0.05 versus intact females of the same respective groups (control or UCMS).
Figure 8. Dilator responses of aortic rings to increasing concentrations of methacholine from OVX LZR under
control conditions and after eight weeks of UCMS.

Panels A present data describing dilator responses under

untreated conditions in control and UCMS OVX LZR versus intact control and UCMS female LZR. Panel B
compares the dilator responses to methacholine in UCMS male LZR versus UCMS OVX LZR. Panel C shows the
dilator responses from OVX control LZR, following pre-treatment with L-NAME, indomethacin or combination.
Panel D present data describing dilator responses from OVX UCMS LZR, following pre-treatment with LNAME, indomethacin or combination. Control female LZR n=8; Control OVX LZR n=8; UCMS female LZR
n=8, UCMS OVX LZR n=8. *p<0.05 versus dilator response in untreated vessel of intact control LZR; † p<0.05
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versus dilator responses in control OVX LZR; ‡ p<0.05 versus dilator responses in untreated vessels of the same
group (control or UCMS).
Figure 9. Dilator responses of aortic rings to increasing concentrations of methacholine from OVX OZR under
control conditions and after eight weeks of UCMS.

Panels A present data describing dilator responses under

untreated conditions in control and UCMS OVX OZR versus intact control and UCMS female OZR. Panel B
presents data describing dilator responses from control OVX OZR, following pre-treatment with L-NAME,
indomethacin or combination. Panel C present data describing dilator responses from UCMS OVX OZR,
following pre-treatment with L-NAME, indomethacin or combination. Control female OZR n=8; Control OVX
OZR n=8; UCMS female OZR n=8, UCMS OVX OZR n=8. *p<0.05 versus responses in intact control OZR; ‡
p<0.05 versus dilator responses in untreated vessels of the same group (control or UCMS).
Figure 10. Dilator responses to increasing concentrations of methacholine in aortic rings of UCMS OVX LZR
and OZR following pretreatment with TEMPOL. Panel A presents data from UCMS OVX LZR under untreated
conditions and following pre-treatment with TEMPOL, Panel B presents data from UCMS OVX OZR under
untreated conditions and following pre-treatment with TEMPOL, Control OVX LZR n=8; Control OVX OZR
n=8; UCMS OVX LZR n=8, UCMS OVX OZR n=8. *p<0.05 versus dilator response in the respective untreated
vessel of OVX females (LZR or OZR).

86

Table 1. Baseline characteristics of male and female LZR and OZR within the present study. *p<0.05 versus control animals of same group (LZR
or OZR).
LZR-M
Control
(n=8)

LZR-F
Control
(n=8)

LZR-M
UCMS
(n=8)

LZR-F
UCMS
(n=8)

OZR-M
Control
(n=8)

OZR-F
Control
(n=8)

OZR-M
UCMS
(n=8)

OZR-F
UCMS
(n=8)

Weight (g)

391±4.1

229±5.6

422±14

244±2.8

596±48

572±22

661±14

535±11

MAP (mmHg)

106±0.7

109±1.5

110±2.6

113±1.2

132±12

132±0.8

137±4.1

142±3.7*

Glucose (mg/dL)

123±7.6

114±6.5

154±6.4*

136±6.5*

166±9.1

131±9.2

186±15

158±8.2

Insulin (ng/mL)

2.4±0.7

1.0±0.7

1.7±0.6

1.8±0.3

18±9.6

6.1±1.9

7.3±3.1

4.8±0.9

Leptin (ng/mL)

25±5.4

17±2.3

15±2.3

22±5.4

102±32

79±5.0

109±18

102±10

TNFα (pg/mL)

2.9±0.6

2.9±0.9

5.3±0.1*

6.5±1.0*

4.0±0.6

5.7±0.7

6.1±0.7*

8.8±1.3*

IL-6 (pg/mL)

16±3.3

2.1±1.1

30±4.6*

38±13*

8.1±1.6

19±1.1

61.1±15*

77±9.3*

IL-1β (pg/mL)

6.3±3.2

6.2±1.2

10.6±2.0

13±2.4*

5.1±1.2

9.0±2.3

13±3.4*

16±5.8

Corticosterone
(ng/mL)

87±3.5

176±26

105±12*

319±49*†

111±15

146±28.5

289±48*

360±43*
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Table 2. Baseline characteristics of OVX females compared to their respective intact females. *p<0.05 versus OVX control of same group (LZR or
OZR), † p<0.05 versus intact females of similar group (LZR or OZR) and condition (control or UCMS).

LZR-F
Control
(n=8)

LZR-F
UCMS
(n=8)

OVX-LZR
Control
(n=8)

OVX-LZR
UCMS
(n=8)

OZR-F
Control
(n=8)

OZR-F
UCMS
(n=8)

OVX-OZR
Control
(n=8)

OVX-OZR
UCMS
(n=8)

229±5.6

244±2.8

302±7.4†

285±4.8†

572±22

535±11

593±15

585±9.7†

108±1.5

114±1.2

107±4.3

117±3.8

132±0.8

140±3.7

142±6.1

145±6.6

114±6.5

136±8.5

190±12†

205±16†

131±9.2

158±8.2

170±11†

157±10

TNFα
(pg/mL)

2.9±0.9

6.4±1.1

7.0±0.5†

7.1±0.4

5.7±0.7

8.8±1.3

9.1±1.0†

7.8±0.3

IL-6 (pg/mL)

2.1±1.1

30±13

50±7.9†

75±11*†

19±1.1

77±9.3

75±13†

57±12

IL-1β
(pg/mL)

6.2±1.2

13±2.4

12±4.6

15±1.4

9±1.3

14±5.5

15±2.0†

14±3.2

Weight (g)
MAP
(mmHg)
Glucose
(mg/dL)

88

A
LZR-M Control
LZR-M UCMS
LZR-F Control
LZR-F UCMS * †

6
5

Coat Score

8

4
3

*†

2

*†
*

*

*†
*†
*

*†

*†

7

*

6

*

Coat Score

7

*

B

OZR-M Control
OZR-M UCMS
OZR-F Control
OZR-F UCMS
*

5

*
*

*
*

*

*
*

*

4
3

1

2

0

1
0
0

1

2

3

4

5

6

7

8

120

Latency to Groom (s)

100

0

1

2

3

4

5

6

7

8

Week(s)

Week(s)

C
Control
UCMS * †

*
*

80
60

*

40
20
0

LZR-M

LZR-F

OZR-M

OZR-F

Figure 1
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A

7

OZR M Control
OZR F Control
OZR M UCMS
OZR F UCMS *

6

4
3

LZR M Control
LZR F Control
LZR M UCMS
LZR F UCMS

2
1
0

Developed Tension (g)

5

Developed Tension (g)

B

5
4
3
2
1
0
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CHAPTER 2: CONCEPTUAL FRAMEWORK
The conclusions from the study presented in this chapter addressed each of the three main questions that
arose from the work presented in chapter one. These findings can be summarized as follows:
-Imposition of UCMS on both male and female LZR and OZR resulted in the development of depressive
behaviors, as well as impairment of endothelial function in aortic rings of all animals. As expected with UCMS,
female LZR developed more severe depressive behaviors, yet females exhibited less severe impairment of
endothelium-dependent dilation to methacholine compared to males. UCMS resulted in hyperglycemia in male
and female LZR, along with increased levels of the corticosterone and inflammatory biomarkers TNF-α, IL-1β,
and IL-6.
- Pre- treatment with L-NAME in aortic rings had minimal effects on vascular reactivity in UCMS male LZR,
while the blunted dilator responses were further impaired as a result of COX inhibition with indomethacin,
suggesting that a dependence on dilator influence of arachidonic acid metabolites (likely PGI2) helps to maintain
vascular reactivity in the compromised state. In contrast, L-NAME blocked dilation in UCMS female LZR, while
indomethacin had a less striking effect. These findings largely corroborate with those of chapter 1, and confirm
that the behavioral and vascular effects of UCMS in mice extend across species to that of a rat model.
- Imposition of UCMS on male and female OZR resulted in the worst behavioral outcomes, as well as the most
severe impairments in vascular function. Importantly, the vascular protection to UCMS-induced vasculopathy
observed in lean females was no longer exhibited in female OZR, as blunted vasodilator response to agonist
challenge was not significantly different from that of male OZR (nor in behavior outcome). Plasma glucose,
corticosterone, and inflammatory biomarkers were all significantly elevated in UCMS male and female OZR
compared to UCMS male and female LZR. Overall, the co-morbid presence of pre-existing metabolic syndrome
resulted in amplification of the deleterious effects of UCMS on the vasculature, and eliminated the sex-specific
vascular protection seen in UCMS female LZR. Interestingly, even in the absence of exogenous stress, male and
female OZR (control) developed depressive like symptoms, suggesting the presence of a bidirectional relationship
between CVD and depression observed in clinical studies showing that adverse CV events are risk factors for
depression. Alternatively, this may be related to the genetic make-up of the OZR, which possess a mutation in the
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leptin receptor (LepRb), resulting in chronically elevated leptin and impaired leptin signaling in the brain, which
has been linked to both central and peripheral processes, as well as depressive behaviors.
- Finally, UCMS-induced vascular dysfunction was increased while behavioral outcomes were attenuated in OVX
animals, both lean and obese. Generally, the effects of OVX had a greater impact on vascular function in LZR (vs
OZR), resulting in similar levels of impaired behavioral and vascular responses to that of UCMS male LZR. OVX
LZR and OZR demonstrated elevated plasma glucose and inflammatory markers compared to control female LZR
and OZR, respectively. These results suggest that loss of female sex hormones contribute to a pro-inflammatory
and pro-oxidative environment in the vasculature.
In sum, the results of this study strongly support the role of inflammation and reduced NO bioavailability in
the development of depressive behaviors and vascular impairments in both male and female, and lean and obese,
animals. The loss of female estrogen resulted in elevated levels of inflammation and worsened vascular responses,
suggesting that normal hormone levels in female animals positively regulate NO bioavailability and reduce the
deleterious effects on vascular inflammation. As outlined in the introduction to this dissertation, the sex hormone
estrogen has vasculoprotective effects via promotion of vascular NO production by endothelium and enhancement
of anti-oxidant defenses.
The spontaneous development of depressive symptoms in OZR demonstrated by these results is supported by
previous behavioral studies using this animal model, and this brings up an interesting avenue for further
investigation. As increasing evidence supports the concept of clinical depression as a disease of chronic sub-acute
inflammation, with clear parallels in terms of biomarker expression that are comparable to those for elevated
CVD risk, would regulation of inflammation and/or oxidative stress, through either sustained physical exercise or
pharmacological interventions, lead to improved vascular and behavioral outcomes? Is there an intrinsic property
within evolution of the metabolic syndrome that can cause development of depressive symptoms in rodents?
Treatments that target systemic pathologies of the metabolic syndrome may significantly improve both
cardiovascular and behavioral function, resulting in the most beneficial effects on health outcomes. The third
chapter of this dissertation will then aim to determine if chronic treatment of CVD risk factors will improve both
vascular function and behavioral responses. To investigate this, a cohort of male OZR was subjected to 9 to 10100

weeks of treadmill exercise or chronic treatment with different pharmacological agents commonly used to control
risk factors of metabolic syndrome
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ABSTRACT
While the increased prevalence and severity of chronic depressive symptoms and elevated cardiovascular
disease risk represent two of the most challenging public health issues in developed economies, the growing
realization of their combined presentation presents a special challenge for not only cardiovascular health
outcomes, but also for effective treatment/interventions. The obese Zucker rat (OZR), a model of the metabolic
syndrome with significant elevations in cardiovascular disease (CVD) risk spontaneously develops significant
depressive symptoms in parallel with the progression of the metabolic syndrome; thus representing a particularly
compelling model for study. To interrogate the relationships between CVD risk factors and depressive symptoms,
we chronically treated OZR with traditional interventions targeted against CVD risk to determine the impacts on
not only vascular function but also on behavioral outcomes and depressive symptom severity. While most of the
employed interventions (chronic exercise, anti-hypertensive, anti-dyslipidemia, anti-diabetic) were differentially
effective at improving vascular function, only those interventions that also resulted in a significant improvement
to both oxidant stress and inflammation and their associated sequelae were also effective at blunting the severity
of depressive symptoms. This initial study provides for a very compelling framework from which to further
interrogate the links between CVD risk and cognitive/behavioral status, and begins to provide insight into the
mechanistic links between the two and potentially effective avenues for intervention.
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INTRODUCTION
It is well known that the growing incidence and prevalence of the metabolic syndrome presents a
consistent threat to aggregate public health cardiovascular outcomes across many societies (1, 11, 24, 28, 33).
This syndrome is broadly defined as the combined presentation of obesity, impaired glycemic control, atherogenic
dyslipidemia, and hypertension, with the additional contributing conditions of a pro-oxidant, -thrombotic, and inflammatory phenotype (11, 24). This clinical condition afflicts a growing number of patients worldwide,
demonstrating substantial reduction in both patient quality of life (1, 28) and life expectancy (24, 33). Given both
the individual detriment to patient health, and the substantial societal economic burden in terms of direct and
indirect economic costs, (20, 35, 37), further detailed investigations into this multi-pathology state are warranted.
The obese Zucker rat (OZR; fa/fa) is an excellent model for the development of the metabolic syndrome
and the associated negative vascular outcomes in humans. Due to a genetic mutation in the leptin receptor that
causes severe leptin resistance, OZR manifest chronic hyperphagia that ensures rapid development of the systemic
pathologies (previously mentioned) to the degree of severity characterized in human subjects. In addition to
metabolic syndrome, OZR suffer from a progressive vasculopathy that ultimately progresses into overt peripheral
vascular disease (26, 40), albeit one in the absence of significant atherosclerotic lesions. However, it has been
recently determined that OZR progressively develop compromised behavioral patterns (without use of additional
intervention treatments) indicative of chronic stress and depressive symptoms (2) , as well as significantly
elevated circulating cortisol and corticosterone levels (6, 10, 29).
This is particularly intriguing as the presence of chronic stress and depressive symptoms have been
identified as a powerful, independent risk factor for negative cardiovascular and cerebrovascular (31, 38, 39)
outcomes. The significant reduction in patient quality of life, profound economic costs, and extreme social
burden associated with depressive disorders (7, 21, 22, 27, 32, 41), coupled with the adverse societal effects of
metabolic syndrome, present a global health problem that has emerged as one of the most challenging public
health issues to date as the combined presence of these diseases continue to rise. While the use of selective
serotonin/norepinephrine reuptake inhibitors (SSRI/SNRI), tricyclic antidepressants, and other pharmacological
agents against depressive symptoms has been extensively investigated (9, 25), specifically with regards to their
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potential impact on cardiovascular function (5, 12, 25), the spontaneous development of significant depressive
symptoms in OZR suggests a different approach may be warranted – that of treating the constituent pathologies of
the metabolic syndrome and determining the impact on depressive symptomology.
The overarching purpose of the present study was to determine the efficacy of chronic interventions (both
pharmacological and physiological) in preventing the development of both behavioral and vascular impairments
that progressively occur with age in OZR. Experimental interventions targeting pathological components of the
metabolic syndrome were implemented at an early age, preceding the development of CVD and depressive
symptoms in OZR, to determine the most beneficial venues for improving ex vivo vascular function and
blunting/reversing depressive symptom severity. With the appropriate and judicious use of chronic interventions,
and analytical approaches, the secondary purpose of the present study was to provide justified identification of the
central mechanistic links which exist between metabolic syndrome, vascular/perfusion dysfunction, and
depressive symptomology. The present study was designed to test the integrated hypothesis that chronic targeted
treatment against the systemic progressive pathologies of the metabolic syndrome results in significant
improvements to both cardiovascular and behavioral function and provide for the maximum potential
improvements to long term health outcomes.

MATERIALS AND METHODS
Animals: Male lean (LZR) and obese Zucker rats (OZR) were delivered to the West Virginia University Health
Sciences Center at 6-7 weeks of age, and after one week of acclimation to the local environment, we placed into a
specific protocol for the subsequent 9-10 weeks. Unless otherwise stated (below), all animals were fed standard
chow and tap water ad libitum for all experiments. All rats were housed in the animal care facility at the West
Virginia University Health Sciences Center, and all protocols received prior IACUC approval. At 7-8 weeks of
age, LZR and OZR (n=12 for each group) were placed into one of the following groups for the subsequent 9-10
weeks:
1. Time control (normal food and water ad libitum)
2. Chronic treadmill exercise (20 m/min, 5% incline, 60 minutes/day, 6 days/week)
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3. Anti-hypertensive treatment with captopril (angiotensin converting enzyme inhibitor; 60 mgkg-1day-1;
drinking water; 17)
4. Anti-hypertensive treatment with hydralazine (systemic vasodilator; 50 mgkg-1day-1; drinking water; 17)
5. Anti-diabetic treatment with metformin (hepatic gluconeogenesis inhibitor; 300 mgkg-1day-1; drinking
water; 17)
6. Anti-diabetic treatment with rosiglitazone (insulin sensitizing agent; 10 mgkg-1day-1; mixed with food; 17)
7. Anti-dyslipidemia treatment with atorvastatin (HMG Co-A reductase inhibitor; 25 mgkg-1day-1; mixed with
food; 17)
8. Anti-dyslipidemia treatment with gemfibrozil (peroxisome proliferator-activated receptor alpha (PPARα)
activator; 100 mgkg-1day-1; mixed with food; 17)
9. Anti-oxidant treatment with TEMPOL (10-3 M; drinking water; 17)
Following completion of the 9-10 week treatment period, a behavioral assessment was conducted on each
animal that included a determination of coat status (36).
Coat Status/Score: This evaluation addresses chronic grooming behavior. A research assistant completed a visual
inspection of the animal prior to usage and evaluated the coat status of the animals. A total cumulative score was
computed by giving an individual score of 0 (clean) or 1 (dirty) to eight body parts (head, neck, dorsal coat,
ventral coat, tail, forelimb, hind-limb, and genital region).
At the time of final usage, rats were anesthetized with injections of sodium pentobarbital (50 mgkg-1
i.p.), and all rats received tracheal intubation to facilitate maintenance of a patent airway. In all rats a carotid
artery and an external jugular vein were cannulated for determination of arterial pressure and for intravenous
infusion of additional substances as necessary (e.g., anesthetic, heparin, etc.). In addition, an aliquot of mixed
venous blood was drawn from the jugular vein cannula for a full profiling of metabolic, endocrine and
inflammatory biomarkers (see below), and each animal received a bolus injection of heparin to temporarily reduce
the occurrence of blood coagulation without jeopardizing vascular reactivity (100 IUkg-1).
Skeletal Muscle Arteriolar Reactivity: Following the initial surgery, an incision was made into the medial upper
hind limb and the extra-parenchymal resistance artery/first order arteriole supplying the gracilis muscle was
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identified. This vessel was cleared of all surrounding tissue along its length and into the gracilis muscle.
Subsequently, the section of the vessel that was fully within the gracilis muscle was removed and doubly
cannulated on glass micropipettes using a previously well-established procedure (3). At this point, hind limb
conduit arteries were removed from the rat (e.g., femoral, popliteal, saphenous), cleaned, and placed in cold PSS
for subsequent determination of specific signaling metabolites relevant for vascular reactivity (see below). The
reactivity of isolated arteries was assessed in response to increasing concentrations of acetylcholine (10-10 M – 10-6
M).
Determination of Signaling Molecule Bioavailability: All harvested conduit arteries from each rat were lightly
sectioned into segments of ~1 mm in length and placed in a chamber for study, superfused with warmed (37C)
PSS equilibrated with 95% O2 and 5% CO2.

Vascular nitric oxide (NO) production was assessed using

amperometric sensors (World Precision Instruments, Sarasota, FL). A NO sensor (ISO-NOPF 100) was inserted
into the chamber and a baseline level of current was obtained. Subsequently, increasing concentrations of
methacholine (10-10–10-6 M) were added to the bath and the changes in current were determined. Subsequently,
vascular production of 6-keto-prostaglandin F1α (6-keto-PGF1α; the stable breakdown product of PGI2), and 11dehydro-thromboxane B2 (11-dehydro-TxB2; the stable plasma breakdown product of TxA2) in response to
challenge with arachidonic acid (10-5 M) was measured. Pooled, sectioned arteries were left untreated for 30
minutes under control conditions (after which the superfusate was removed and frozen in liquid N 2) and were
allowed to incubate with the introduced arachidonic acid for an additional 30 minutes (followed by superfusate
removal and storage). Vessel weights were determined after blotting on gauze to remove excess liquid, and
metabolite release by the vessels was determined using commercially available EIA kits for 6-keto-PGF1α and 11dehydro-TxB2 (Cayman).
Data and Statistical Analyses: To simplify analyses, individual biomarkers of key parameters were combined
into groups to provide aggregate estimators of the severity of the degree of dysfunction. While coat score and
cortisol levels were not manipulated, integrated vascular reactivity was estimated as the upper bound of the
acetylcholine concentration-response relationship (see below).

The levels of glycemic control, referred to

HOMA, was estimated as the product of plasma insulin concentration multiplied by blood glucose concentration,
107

where higher values clearly represent poorer glycemic control.

The severity of the oxidant stress and

inflammatory state, referred to as Oxidant Load, was defined as the product of plasma nitrotyrosine concentration
multiplied by plasma TNF-α concentration, with that product divided by the slope of the nitric oxide
bioavailability curve, where higher values represents pro-oxidant, pro-inflammatory states with low NO
bioavailability. The balance of arachidonic acid metabolism in the vasculature was estimated as the quotient of
PGI2 and TxA2 production, and is referred to as AA Met Balance, where higher values represent optimal health
and lower CVD risk.
All data are presented as mean±SEM. Statistically significant differences in measured physiological
parameters, calculated physiological parameters (e.g., slope coefficients, upper or lower bounds), measurements
of plasma biomarkers, were determined using analysis of variance (ANOVA). In all cases, Student-NewmanKeuls post hoc test was used when appropriate and p<0.05 was taken to reflect statistical significance. The
mechanical responses of ex vivo microvessels following agonist challenge were fit with the three-parameter
logistic equation:

 max  min 
y  min  
log ED50 x 
1  10

where y represents the change in arteriolar diameter, “min” and “max” represent the lower and upper
bounds, respectively, of the change in diameter or tension with increasing agonist concentration, x is the
logarithm of the agonist concentration and logED50 represents the logarithm of the agonist concentration ( x ) at
which the response ( y ) is halfway between the lower and upper bounds.
Vascular NO bioavailability measurements were fit with a linear regression equation (𝑦 =∝0 + 𝛽1 𝑥);
where y represents the NO concentration, ∝0 represents an intercept term, 𝛽1 represents the slope of the
relationship, and 𝑥 represents the log molar concentration of methacholine.
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RESULTS
Table 1 summarizes the baseline characteristics of animals utilized in the present study.

While OZR

were consistently heavier than LZR and demonstrated all of the phenotypes of the metabolic syndrome, the
employed interventions were effective at reducing the severity of their respective CVD risks, with exercise being
able to broadly reduce CVD risk in parallel with the reduced severity of obesity.
Figure 1 presents the univariate relationship between individual animal cortisol and coat score for control
LZR and OZR (Panel A) and for all of the animals (Panel B) within the present study. As is clearly evident from
these data, there was a strong positive relationship between the levels of plasma cortisol and the degradation in the
coat status for the individual animals. This provides a strong level of support for the overriding conceptual model
for the present experiment is that coat score and plasma cortisol levels are general indicators of behavioral status
(chronic stress and depressive symptoms) in LZR and OZR.
The initial analyses of the data focused on a univariate approach correlating our predictive markers to
outcomes. Figure 2 (for coat score) and Figure 3 (for plasma cortisol) summarizes these basic analyses, and
clearly demonstrates a robust univariate relationship between our predictive markers of the upper bound of the
acetylcholine concentration-response relationship (Panel A), our measure of insulin resistance (Panel B), our
integrated measurement of oxidant/inflammation stress (Panel C) and the measurement of altered arachidonic acid
metabolism (Panel D) for control LZR and OZR. However, the extent to which these parameters are correlated to
the coat score and plasma cortisol outcomes is less robust as data from OZR following the imposed interventions
of the present study for the acetylcholine upper bound (Panel E), insulin resistance (Panel F),
oxidant/inflammation stress (Panel G) and arachidonic acid metabolism (Panel H).
Given the increasing weakness of the relationships between the predictive parameter and the behavioral
outcomes, it was necessary to identify the relationships between coat score, plasma cortisol and our predictive
parameters.

Figure 4 presents the relationship between coat score, cortisol and the upper bound of the

acetylcholine-dose response relationship in control LZR and OZR. This relationship (which is qualitatively very
similar to the other three predictors; data not shown) clearly demonstrates the negative correlations between
upper bound and either cortisol levels or coat score, while also demonstrating the positive relationship between
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coat score and cortisol levels (Panel A). The individual animal relationships grouping coat score, plasma cortisol
and acetylcholine upper bound are summarized in Panel B, which demonstrates the effectiveness of chronic
treatments with TEMPOL or atorvastatin or chronic exercise in terms of improving both vascular and behavioral
outcomes, while chronic gemfibrozil, anti-hypertensive, or anti-diabetic treatments were less effective at
improving aggregate outcomes. However, for the interventions that resulted in a significant improvement to coat
score and cortisol (chronic exercise, atorvastatin and TEMPOL treatment), this was associated with a significant
improvement to the upper bound of the acetylcholine concentration-response relationship (Panel C), while those
interventions that did not result in an improvement to the behavioral markers of coat score and cortisol levels
(gemfibrozil, metformin, hydralazine, rosiglitazone), were also not associated with an improvement to vascular
function (from the upper bound relationship; Panel D).
Figure 5 presents the data describing the ability of the interventions from the present study to restore
normal function (that determined in LZR control) from the maximum level of dysfunction (OZR control) for the
parameter in question. For both coat score (Panel A) and cortisol (Panel B), chronic exercise, atorvastatin and
TEMPOL treatment resulted in a consistent restoration of greater than 30-40% of the maximum possible (i.e.,
full) recovery in terms of these two parameters describing behavioral outcomes. In contrast, treatment with
gemfibrozil, metformin, captopril, hydralazine, or rosiglitazone had a much less significant and consistent effect
on either coat score or plasma cortisol levels. Building on this, the impact of the chronic interventions to improve
vascular reactivity (Panel C), glycemic control (Panel D), oxidant stress and inflammation (Panel E) and to restore
normal arachidonic acid metabolism (Panel F), all demonstrated a similar trend, with exercise and atorvastatin
treatments being most effective at improving these parameters back to the levels determined in LZR controls.
With the single exception of glycemic control, chronic TEMPOL treatment was also most consistently effective at
restoring the four parameters to normal levels of function.
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DISCUSSION
One of the more intriguing observations from epidemiological and public health research is the
remarkably tight relationship that exists between the prevalence and severity of depressive symptoms within the
population and the concurrent development of elevated cardiovascular disease risk. This opens up wide series of
questions and issues to be addressed in terms of the parallel development of these systemic conditions, their
health outcomes, issues of disparity, and policy adaptations to address this, but these are outside of the scope of
the present study.
While there exist a wide array of studies demonstrating a variable level of efficacy of classic
pharmacological interventions for the treatment of depressive symptoms (9, 25), many of these have a wide array
of undesirable, and at times long-lasting, side effects that can limit patient adherence (5, 9) or result in a “trade
off” of one compromised facet of quality of life for others.
In preliminary studies, we have recently determined that the OZR begins to develop many of the
hallmarks of increased depressive symptom severity in parallel to the development of the constituent pathologies
of the metabolic syndrome (2).

These observations include a steadily decreasing level of physical

activity/increasingly sedentary behavior, an increased plasma cortisol level, and a steady, progressive failure to
groom that precedes the development of severe obesity (which would physically preclude grooming). As has also
been repeatedly demonstrated by multiple laboratories, the OZR also develops significant impairments to normal
vascular function, including alterations to dilator (13, 19, 23, 43) and constrictor (4, 14, 16, 30) reactivity, vessel
structure (18), vascular network structure (15) and perfusion responses (16, 34, 42), in the skeletal muscle
circulation. Clearly, with the myriad alterations occurring in parallel in the OZR, there is the potential for these to
create integrated systems where one impairment to vascular function, can predispose the animal to impaired
cerebral function (or vice versa), with the aggregate output being a progressive development of the symptomology
of both peripheral vascular disease and depressive behaviors. The purpose of the present study was to determine
if chronic interventions targeted at cardiovascular disease risk reduction would not only improve vascular
outcomes, but if this would also improve behavioral responses through a reduction in markers of depressive
symptom severity.
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The initial responses of the present study demonstrate that the five employed predictors of the general
behavioral response (coat score or cortisol) are all strong, univariate correlates of the behavioral outcomes in
control (untreated) LZR and OZR throughout the age ranges from 7-8 weeks to ~17 weeks (Figures 2 and 3).
However, when additional data are added following the interventions, the correlations are weakened considerably,
suggesting that some of the interventions result in a condition wherein the ability of the outcome “vascular”
parameters to predict behavioral responses becomes less robust. This strongly suggests that the conditions that
are created, although potentially improving vascular outcomes are not sufficient to impact behavioral ones, and
thus are less effective treatments overall. However, this analysis is insufficient from which to draw further
insight.
Building on this, we determined the “normal” relationship between vascular function, behavioral
outcomes (i.e., coat score) and plasma cortisol (as the parameter that can link the two). These data, summarized
in Figure 4, provide for a robust understanding of this relationship, where poor vascular function (low upper
bounds for the acetylcholine concentration-response relationship) was associated with high levels of plasma
cortisol and high coat scores. Using the present data, it is relatively clear to see that few interventions (i.e.,
chronic exercise, TEMPOL and atorvastatin) were most effective at improving coat score in OZR, while the other
interventions, while still effective at improving specific outcomes, produced a less robust improvement to the
behavioral measures.

When compared to the normal relationships between vascular function, cortisol and coat

score between LZR and OZR, it is clear that the three successful interventions were more effective at shifting the
aggregate relationship to improved vascular function, lower cortisol and improved coat score, while those
interventions that were less effective may have improved vascular function per se, but were less effective at
impacting cortisol or coat score.
This determination led to the obvious question of what distinguishes one intervention from the others in
terms of improving both behavioral and vascular outcomes. To address this, we utilized our six parameters of
outcomes (coat score, cortisol, ACh upper bound, HOMA, oxidant load and AA metabolism balance) and
determined the ability of the individual interventions to restore normal function (i.e., that determined in LZR)
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from the maximum degree of impaired function (i.e., that determined in OZR), with full restoration defined as
100%.
The results of these analyses clearly demonstrated the divergence in the effectiveness of treatment
interventions. Chronic exercise and chronic treatment with atorvastatin were consistently able to cause significant
improvements to all of the key parameters utilized for the present study. Similarly, chronic treatment with
TEMPOL was also extremely effective at improving 5 of the 6 outcome parameters of the present study. In
contrast none of the other imposed treatments were able to cause significant improvements to more than 3 or 4
(captopril only) of the key parameters utilized.
These data raise the clear question of what are the mechanistic underpinnings of the most effective
interventions such that they were able to improve both vascular and behavioral function significantly. While a
detailed determination of these mechanisms and how they interrelate will likely be quite complex and is well
beyond the scope of a single manuscript, clear inferences can be derived based on what was and what was not
effective. Clearly, in order for the intervention to be effective, the primary outcome must be a significant
attenuation of both chronic inflammation and chronic elevations to oxidant stress. While these are both wellestablished outcomes of chronic exercise (15), chronic treatment with TEMPOL (13) and as the pleiotropic effects
of chronic treatment with atorvastatin (18), their effect on improving outcomes appears to go beyond simply
improving vascular function (as other interventions that also improve vascular function are less effective at
correcting behavioral outcomes).
Given an increasing emphasis and recognition of both cardiovascular disease risk factors (8, 11, 28) and
clinical depression (9,25) as diseases strongly associated with chronic elevations in oxidant stress and sub-acute
inflammation, it is perhaps not surprising that these three interventions (exercise, TEMPOL and atorvastatin) are
most able to positively impact both vascular function and behavioral outcomes. However, while these studies are
very provocative, they highlight the need to identify whether these relationships are also present in the cerebral
circulation, which may have a much more direct impact on the behavioral responses, and if there are specific
mechanistic links at a higher resolution that can be exploited with future interventional efforts. Most importantly,
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these results highlight the potential utility of a novel use of established therapeutics for CVD risk that may
provide significant relief from the devastating impact of chronic depressive symptoms.
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Table 1. Baseline characteristics of animal groups within the present study. Abbreviations: EX (exercise), CAP (captopril), HDZ (hydralazine), MET
(metformin), RGZ (rosiglitazone), TEM (TEMPOL), ATOR (atorvastatin), GEM (gemfibrozil); * p<0.05 vs. LZR; † p<0.05 vs. OZR.

7-8

148±7

340±8*

OZREX
(n=8)
328±12

16-17

308±9

688±14*

570±14*

680±10*

679±12*

672±12*

681±7*

667±12*

374±10*

690±8*

7-8

104±4

102±5

101±4

98±4

102±6

97±6

100±5

100±5

99±4

102±6

16-17

105±6

134±7*

124±6*

104±6†

101±5†

128±7*

120±5*

118±5*†

125±5*

114±6*†

7-8

84±5

88±5

91±6

92±6

91±6

88±7

92±6

92±6

94±6

92±4

16-17

94±4

128±7*

114±8*

111±9

125±7*

106±5†

99±6†

118±6*

125±8*

119±6*

0.9±0.2 5.8±0.5*

5.5±0.6*

5.5±0.4*

5.4±0.7*

5.4±0.5*

5.6±0.5*

5.7±0.6*

5.5±0.5*

5.2±0.4*

1.3±0.2 8.4±0.5* 5.8±0.7*†

6.2±0.6*†

8.0±0.7*

4.7±0.7*†

4.2±0.5*†

6.0±0.6*†

6.5±0.6*†

6.8±0.5*†

Weeks LZR
(n=8)
Mass
(g)
MAP
(mmHg)
Glucose
(mg/dl)
Insulin
(ng/ml)
N-tyrosine
(ng/ml)

7-8
16-17

OZR
(n=8)

OZRCAP
(n=8)
338±9*

OZRHDZ
(n=8)
348±7*

OZRMET
(n=8)
331±8*

OZRRGZ
(n=8)
344±6*

OZRATOR
(n=8)
340±11*

OZRGEM
(n=8)
337±8*

OZRTEM
(n=8)
351±6*

7-8

8±3

17±3*

16±2*

16±5

17±4

15±5

16±5

18±4*

16±5

17±4

16-17

14±4

54±8*

35±5*†

40±7*

47±7*

26±4*†

24±5†

38±6*†

41±6*

22±6†
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FIGURE LEGENDS
Figure 1. Correlations between plasma levels of cortisol and aggregate coat score in male LZR and OZR
between age ranges 7-8 weeks and 16-17 weeks. Data are presented from individual animals under untreated
conditions (control; Panel A) and following all chronic interventions (exercise, anti-oxidant, anti-hypertension,
anti-diabetes, anti-dyslipidemia; Panel B)

The line of best fit through the data are is also presented for each

relationship. Please see text for details.

Figure 2. Correlations between aggregate coat score and the key outcome parameters in the present study for
male LZR and OZR between age ranges 7-8 weeks and 16-17 weeks. Data are presented from individual animals
versus the upper bound of the acetylcholine concentration-response curve (ACh Upper Bound; Panels A or E), the
index of glycemic control (HOMA; Panels B or F), the index of oxidant stress/inflammation (Oxidant Load;
Panels C or G) and the index of arachidonic acid metabolism (AA Metab; Panels D or H) in untreated control
conditions or following chronic interventions, respectively. The line of best fit through the data is also presented
for each relationship (r2 > 0.75 for all). Please see text for details.

Figure 3. Correlations between plasma cortisol levels and the key outcome parameters in the present study for
male LZR and OZR between age ranges 7-8 weeks and 16-17 weeks. Data are presented from individual animals
versus the upper bound of the acetylcholine concentration-response curve (Ach Upper Bound; Panels A or E), the
index of glycemic control (HOMA; Panels B or F), the index of oxidant stress/inflammation (Oxidant Load;
Panels C or G) and the index of arachidonic acid metabolism (AA Metab; Panels D or H) in untreated control
conditions or following chronic interventions, respectively. The line of best fit through the data are is also
presented for each relationship. Please see text for details.

Figure 4. Graphical representation of the normal relationships between the dilator reactivity of skeletal muscle
resistance arterioles to increasing concentrations of acetylcholine, plasma cortisol concentration and aggregate
coat score in untreated (control) male LZR and OZR between age ranges 7-8 weeks and 16-17 weeks (Panel A).
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The raw data from each animal are fit with a smoothing function that integrates a running average between near
neighbor data points. Panel B presents this relationship from each animal within a group following the chronic
interventions utilized in the present study. Panels C and D, represent the relationships in the untreated (control)
LZR and OZR and divides the interventions into those that were effective at improving vascular and behavioral
outcomes (Panel C) and those that were not (Panel D), using the same smoothing function as for Panel A. Please
see text for details.

Figure 5. Data describing the ability of imposed chronic interventions of the present study to restore normal
levels of the key outcome parameters in LZR and OZR in the present study. Data are presented for the
effectiveness of the imposed interventions on coat score (Panel A), plasma cortisol (Panel B), vascular reactivity
(Panel C), glycemic control (Panel D), oxidant stress/inflammation lad (Panel E), and arachidonic acid
metabolism (Panel F). The imposed chronic interventions were exercise (EX), captopril (CAP), hydralazine
(HDZ), metformin (MET), rosiglitazone (RGZ), atorvastatin (ATOR), gemfibrozil (GEM) and TEMPOL (TEM).
The horizontal line in each panel represents an improvement of 30% from the maximum degree of dysfunction for
that parameter.
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CHAPTER 3: CONCEPTUAL FRAMEWORK
This study sought to address whether controlling inflammation and oxidant stress through either the use
of an exercise regimen or chronic pharmacologic treatments would result in improved vascular function and
behavioral outcomes. Several key findings emerged from this study:
- Exercise training and two pharmacological treatments- Atorvastatin and TEMPOL- were able to improve coat
score, as well as reduce cortisol levels. Levels of cortisol corresponded strongly with behavioral outcomes in OZR
animals. As cortisol is the main hormone of the stress response, the strong relationship between cortisol and
behavioral outcome was expected, and the reduction of cortisol from treatments can therefore be taken as the most
significant link towards improved behavioral outcomes.
- Several of the treatments- exercise, Atorvastatin, TEMPOL, Metformin, Captopril, and Rosiglitazone were all
able to improve the oxidant load in OZRs, as well as improve endothelium-dependent dilation to ACh. These
findings support our previous observations that improving NO bioavailability by reducing oxidant stress results in
improved vasodilation to ACh. However, neither improved vascular reactivity nor improved oxidant load were
correlated with improved coat scores and lowered cortisol. Exercise, TEMPOL, and Atorvastatin each were able
to improve both vascular function and behavioral outcomes, while metformin, rosiglitazone, and Captopril had no
impact on behavior or cortisol. These findings indicate that reduction of oxidant stress and improvement of NO
bioavailability alone are insufficient to improve behavior and reduce cortisol.
- Rosiglitazone and metformin both treat glycemic management, and indeed were seen in this study to improve
HOMA; however, these drugs did not improve coat score or cortisol. Captopril controls hypertension, and was
able to reduce oxidant load and strongly improve endothelial function, but was also ineffective at improving
behavior and cortisol. These findings indicate that improved metabolic control and management of blood pressure
are not sufficient to improve behavior or cortisol.
- The three interventions that effectively improved behavior- Atorvastatin, TEMPOL, and Exercise- were also
unique in that they were the only three that improved AA metabolism balance, indicating a shift towards
production of PGI2 and away from TxA2 production. These findings indicate that either improved AA metabolism
alone, or perhaps improved AA metabolic balance coupled with attenuated oxidative stress, may be key
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components mediating behavioral outcomes and cortisol levels in the OZR model of metabolic syndrome.
Improving oxidant load or HOMA alone was not related to AA metabolism, suggesting that improvements in this
metric were an independent effect of exercise, TEMPOL, and Atorvastatin.
Overall, the results of this study indicate that interventions which both reduce levels of oxidant stress and
promote an anti-inflammatory shift in COX metabolism are most effective at improving coat score and reducing
levels of cortisol. Improving oxidant stress and vascular reactivity alone is not sufficient to improve depressive
symptoms. A future expansion of this study should evaluate the prophylactic efficacy of Atorvastatin, exercise,
and TEMPOL towards preventing the induction of depressive symptoms in animals undergoing UCMS.
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DISCUSSION
The purpose of this dissertation was to investigate the effects of chronic stress/depression on behavioral
outcomes and vascular function in rodents in order to elucidate the underlying mechanisms linking depression
incidence with cardiovascular development/outcomes. Animal models of depression are valuable research tools
for investigating the mechanistic contributors and functional outcomes linking depression with vascular disease.
The fundamental concept of the UCMS protocol is that exposure to chronic, uncontrollable, environmental
stressors induces behavioral, psychological, and physiological changes that alter homeostatic balance and the
ability to adapt to subsequent stress challenges. Early work from the laboratory of Catherine Belzung and from
our laboratory demonstrated that UCMS promoted vascular pathologies in healthy BALBc/J mice, and concurrent
studies have confirmed variable responses based on sex. As women are twice as likely to develop depression
compared to age matched men, preliminary data from initial experiments showed a similar trend in which female
rodents were more susceptible to UCMS-induced behavioral changes versus their male counterparts, thereby
leading to our initial exploration of sex differences utilizing the UCMS model.
The first chapter of this dissertation emphasized the variable effects of UCMS on behavioral and
physiological outcomes between male and female BALB/cJ mice. The results showed that compared to UCMS
males, UCMS female animals exhibited a greater susceptibility to behavioral symptoms as measured by
worsening of the coat score, reduced sucrose-stimulated grooming, and increased immobility in the tail
suspension test, as well as increased plasma markers of oxidant stress, inflammation and HPA dysfunction.
However, despite these elevated responses, the developed vasculopathy in both the conduit and resistance
vasculature of female mice was less severe than that of males as evidenced by superior maintenance of
endothelium-dependent vasodilator response to agonist challenge in aortic rings and gracilis arterioles. Much of
this blunted impairment appeared to be a function of a superior maintenance of endothelial function, primarily via
more modest reduction of NO bioavailability and more favorable balance in arachidonic acid metabolism.
Together, these data indicate a greater capacity of females to attenuate the negative effects of chronic
stress/depressive symptoms. Importantly, similar responses were observed between individual female rodents
despite the fact that they were randomized with respect to the time of their estrous cycles, thus vascular and
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behavioral outcomes were not associated with observable differences in hormonal fluctuations, suggesting that
the protective effects may confer a more stable, long standing feature of female physiology. This study provided a
foundation for further investigation into the potential mechanisms involved in the sex disparity related to
differences in prevalence, severity, and outcomes of depression and CVD.
Building on this work, the second chapter investigated the concept of “female protection” from chronic stressinduced effects on adverse vascular health and changes in these outcomes in ovariectomized females. Two
important alterations in experimental approach of Chapter 2 improved the translational relevance of this study:
use of rats, as this species has a more robust background in peripheral vascular disease research as well as a more
comparable CVD pathology to that of human disease; and expansion of the study to include a model of comorbid
depression and CVD. This approach provides mechanistic insight into the integrative system of comorbid
conditions that have an additive effect in promoting adverse CV outcomes. Chapter 2 investigates comorbid CVD
risk and depression in the obese Zucker rat, a model of metabolic syndrome, and the effects of loss of female sex
hormones in OVX females, and the potential overlap of these effects on UCMS induced depressive like behavior
and vascular reactivity.
Imposition of UCMS in LZR resulted in similar sex differences in the development of depressive behaviors,
as well as impairment of vasodilator response demonstrated by results of chapter 1. An unexpected development
of depressive behaviors occurred in male and female OZR in the absence of chronic stress, suggesting that the
genetic make-up of OZR predispose these animals to depressive symptoms, or alternatively, that the development
of behavioral changes is induced by the progressive worsening of metabolic syndrome. Regardless, worsened coat
scores and depressive behaviors in OZR have been previously observed in unpublished work from our laboratory,
and the quantification of depressive behaviors in the non-stressed OZR group provides evidence that the OZR
itself may be a suitable model for studying CVD-related depression. The imposition of chronic stress induced
elevated levels of inflammatory biomarkers and oxidative stress in addition to the damaging effects of
dysfunctional lipid profiles and increased adiposity associated with metabolic syndrome in the OZR model. Our
results clearly showed that pre-existing CVD amplified the deleterious vascular effects of UCMS, and eliminated
the sex-specific vascular protection observed in UCMS female LZR.
131

Finally, these outcomes were investigated in ovariectomized (OVX) female animals. OVX attenuated
behavioral impairment to UCMS, elevated plasma glucose and inflammatory markers, and impaired vascular
endothelial dependent dilator responses, specifically due to increased pro-inflammatory factors, loss of NO
bioavailability, and impaired endothelial reactivity. Interestingly, loss of estrogen promoted these responses in
LZR with or with-out chronic stress, while OVX alone did not alter vascular response in OVX OZR relative to
intact OZR control. An increased risk in CVD is strongly associated with menopause in women, and these results
support the hypothesis that the loss of sex hormones, perhaps in conjunction with the psychological and social
stressors associated with menopause, contributes to the development of vasculopathy. Together, this study
suggests that loss of estrogen-based protection against inflammation and oxidative stress enhances risk of
endothelial dysfunction in lean females, while loss of estrogen in female OZR enhanced the vascular dysfunction
only in conditions of co-morbid CVD and depression. Overall, the results of the second chapter of this dissertation
strongly support the theory that inflammation and oxidative stress are significant contributing factors to the
development of depressive behaviors and vascular impairments in both male and female, and lean and obese,
animals, and that endogenous female sex hormones in lean animals play a significant role protecting the
vasculature against these factors.
The final chapter of this dissertation is built upon key observation gathered from the first two chapters linking
inflammation and oxidative stress with depression and vascular dysfunction. This raises the possibility that
treating these parameters to improve vascular health may also prove effective in attenuating depressive symptoms.
Chronic treatment using common pharmaceutical drugs targeting components of metabolic syndrome including:
hypertension (captopril), peripheral vasoconstriction (hydralazine), glucose regulation (metformin), insulin
insensitivity (rosiglitazone), hypercholesterolemia (atorvastatin), and dyslipidemia (gemfibrozil), were used in
addition to TEMPOL and exercise training, to assess the efficacy in improving vascular function as well as
depressive behaviors (coat score and plasma cortisol).
The normal relationship between vascular function, cortisol and coat score between LZR and OZR clearly
indicated that only exercise, atorvastatin, and TEMPOL, were able to shift responses towards improved vascular
function as well as lower cortisol and reduced coat score, thus attenuating depressive symptom severity. These
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three interventions were also unique in their ability to improve AA metabolism balance, thus favoring a shift
towards production of PGI2 over TxA2. Overall, the results of Chapter 3 indicate that interventions that are most
effective at improving oxidant stress and inflammation are also most effective at decreasing coat score and
reducing levels of cortisol. Improving oxidant stress and vascular reactivity alone is not sufficient to improve
depressive symptoms, suggesting that behavioral outcomes of UCMS are likely related to both an increase in
oxidative stress and inflammation. It is possible that prophylactic efficacy of Atorvastatin, exercise, and TEMPOL
or some combination of the three may therefore attenuate severity of depressive symptoms with UCMS. Of note,
previous work from our laboratory (Frisbee et al., 2011) revealed that functional impairments in skeletal muscle
performance in OZR are the combined result of increased α-adrenergic signaling, oxidative stress, and TxA2
production, and only synergistic treatment of these factors restored skeletal muscle function in OZR. Interestingly,
the same factors (inflammation, oxidative stress, and TxA2 production, as well as adrenergic signaling) are present
in LZR following UCMS, and were further increased in OZR with UCMS. This commonality points to a larger
conceptual framework of CVD pathophysiology, in which a disturbance in the healthy homeostatic balance (e.g.
hypertension, metabolic syndrome, chronic stress/depression, etc.) affects mechanisms regulating vascular tone
and endothelial function, with functional consequences on tissue perfusion in the periphery and development of
depressive behaviors. Additionally, the combination of multiple risk factors would therefore predict an
accelerated and advanced development of vascular dysfunction involving reduced NO bioavailability, increased
TxA2 production, pro-oxidative, pro-inflammatory conditions, and enhanced adrenergic tone. The work detailed
in this dissertation provides compelling evidence in support of such a framework, and demonstrates that
progressive treatment of CVD that targets one component is largely ineffective due to inability to restore
homeostatic balance in the vasculature.
Clinical Significance
Based on the data from this dissertation, a compelling case can be made for a causal relationship between
depression and CVD. Clinical and epidemiological studies have consistently demonstrated a strong association
between depression and cardiovascular morbidity and mortality, with profound differences in clinical presentation
and symptom severity between males and females. Depression has been linked to impairments in vascular and
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endothelial functions, and the roles of inflammation and oxidative stress have been consistently reported as strong
potential mediators (Fiedorowicz, 2014). However, it has been argued that these components explain only a
fraction of the complex integrated relationship between depression and vascular outcomes (Vaccarino et al.,
2007); concurrently, a single biomarker measurement is not able to adequately describe symptom severity or the
variable clinical presentations between sexes, findings that were clearly evident from the experiments outlined in
this dissertation. This underscores one of many challenges that limit the ability for researchers to effectively
address this important public health issue.
Treatment of depression with currently available antidepressant therapies, most commonly SSRIs, has
demonstrated variable clinical effects and limited efficacy, with successful therapeutic effects in less than 50
percent of patients, and in patients that respond initially, a high percentage experience a relapse or recurrence of
depressive episodes after discontinuing treatment (Brosse et al., 2002). Furthermore, antidepressants have not
been established as a means of reducing associated risk of CVD, and may have adverse effects on CV health.
While SSRIs increase levels of serotonin within synapses in the brain, their main anti-depressant effect is thought
to be linked to increasing neurogenesis within the hippocampus (Clayton, 2012). Our results are consistent with
other preclinical reports that suggest that inflammation and oxidative stress are linked to depressive symptoms
(Patki et al., 2015; Xu et al., 2014); we hypothesize that it is therefore possible that a cerebral microenvironment
hostile to neurogenesis may decrease the efficacy of many antidepressant drugs. We can speculate that targeting
both increasing serotonin levels and reducing the oxidant load within in the brain could increase the efficacy of
popular SSRIs and other antidepressants. For example, the common statin drug, atorvastatin, a 3-hydroxy-3methylglutarylcoenzyme A (HMGCoA) reductase inhibitor widely used in clinical practice as a lipid-lowering
agent, has also been reported to have antidepressant effects (Shahsavarian et al., 2014) (similar to the results
shown in Chapter 3). Although the exact mechanisms are not known, protective effects of statins have been linked
to their role as immunomodulatory agents against oxidative stress and inflammation. In addition, data have
indicated that atorvastatin may directly influence neuronal function by modulating important neuropeptides as
well as essential neurotransmitter systems, including serotonergic activity, involved in the pathophysiology of
depression (Ludka et al., 2014). Taken together, it is possible that coupling antidepressants with Atorvastatin or a
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more stable form of an antioxidant drug like TEMPOL could improve treatment efficacy and reduce disease
burden in many patients with depression. Alternatively, Atorvastatin or TEMPOL alone may be effective at
improving depressive symptoms in patients who have comorbid metabolic syndrome or CVD, suggesting that
they possess pleiotropic protective effects in the central nervous system that are associated with depression that
may be independent of their main function on vascular factors.
However, treatment of comorbid CVD and depression may be challenging due to the high complexity of
medications with pleiotropic effects in comorbid diseases. Therefore, non -pharmacological interventions, such as
exercise training, have been reported as successful treatments for depression (Rong-Hui et al., 2014; Craft et al.,
2004). Theoretically, exercise may provide important advantages over pharmacotherapy, including fewer drug
interactions and more involvement of patients in their self-care. Furthermore, reports have shown that exercise
training is as effective as most antidepressants at improving depression symptoms and reducing the incidence of
recurrent episodes (Craft et al., 2004); it has been demonstrated to lead to significant improvements of adverse
pathophysiological effects of depression, including lowered sympathetic nervous system activity, increased heart
rate variability, decreased inflammation, improve CNS functioning, and promote endothelial function (Rong-Hui
et al., 2014).
The significance of this research has far reaching clinical implications, especially as the high prevalence of
comorbid depression and CVD or CV risk factors, including MetS and its components, continue to rise, resulting
in amplification of the deleterious health outcomes that are more complicated and burdensome than the individual
condition itself. Clinicians should therefore strongly consider monitoring patients with depression for CVD, and
vice versa. Additionally, future studies are needed to better understand the specific mechanisms by which elevated
risk of depression itself can become an evidence-based target for intervention on cardiovascular risk, ideally
investigating potential treatment interventions that concomitantly improve both depression and cardiovascular risk
or risk factors, such as Atorvastatin and TEMPOL. This should be an impetus for prioritizing the improved
integration of behavioral and medical care.

135

REFERENCES
1. Vaccarino V, Johnson BD, Sheps DS, Reis SE, Kelsey SF, Bittner V, et al. Depression, inflammation, and
incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung, and
Blood Institute-sponsored WISE study. J Am Coll Cardiol. 2007; 50(21):2044–50.
2. Fiedorowicz JG. Depression and Cardiovascular Disease: An Update on How Course of Illness May Influence
Risk Current Psychiatry Reports.2014; 16:492.
3. Rong-Hui T, Zhi-Yu Z, Guo-Qiang Z, Wei-Feng W, Yun-Juan L, Zhan-Dong B, Yan H, Wei-Qiang H, and LiMei Y. Effects of exercise training on depression in patients with heart failure: a systematic review and metaanalysis of randomized controlled trials. European J of Heart Failure.2014; 16:749–757.
4. Brosse AL, Sheets ES, Let HS, Blumenthal JA. Exercise and the Treatment of Clinical Depression in Adults
Recent Findings and Future Directions Sports Med. 2002; 32(12):741-760.
5. Clayton AH. Understanding antidepressant mechanism of action and its effect on efficacy and safety. Journal of
Clinical Psychiatry. 2012. 73(3):e11.
6. Patki G, Salvo A, Li H, Atrooz F, Isam A, Kelly M, Salin S. Tempol Treatment Reduces Anxiety-Like
Behaviors Induced by Multiple Anxiogenic Drugs in Rats. Plos One. 2015; 10(3):e0117498.
7. Xu Y, Wang C, Klabnik JJ, O’Donnel JM. Novel Therapeutic Targets in Depression and Anxiety: Antioxidants
as a Candidate Treatment. Current Neuropharmacology. 2014; 12(2):108–119.
8. Shahsavarian A, Javadi S, Jahanabadi S, Khoshnoodi M, Shamsaee J, et al. Antidepressant-like effect of
atorvastatin in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway.
European Journal of Pharmacology. 2014; 745:52-8.
9. Ludka FK, Constantino LC, Kuminek G, Binder LB, Zomkowski AD et al. Atorvastatin evokes a serotonergic
system-dependent antidepressant-like effect in mice. Pharmacology Biochem and Behavi. 2014; 122:253-60.

136

10. Craft LL, Perna FM. The Benefits of Exercise for the Clinically Depressed. Primary Care Companion- Journal
of Clinical Pyschiatry. 2004; 6(3):104–111.

137

